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ABSTRACT 
           Mycofactocin is a putative ribosomally synthesized and post-translationally 
modified peptide (RiPP)-derived redox cofactor. Its biosynthesis is accomplished 
through the dedicated actions of the products of six conserved genes, 
mftABCDEF. The mycofactocin pathway is one of the most widely distributed RiPP 
systems in bacteria however, this distribution is heavily skewed towards the 
Mycobacteria genus including human pathogenic variants such as M. tuberculosis 
and M. ulcerans. Gene expression studies have demonstrated the essentiality of 
the pathway in the ability of M. tuberculosis to utilize the host’s cholesterol as sole 
carbon source during latency. However, the biosynthesis, structure and 
physiological function of mycofactocin remain enigmatic. Current efforts to 
elucidate the biosynthesis, structure and function of mycofactocin have focused on 
in vitro reconstitution of each enzyme in the pathway to gain insights into their role 
and function.  
           The biosynthesis of mycofactocin commences with the ribosomal 
production of the precursor peptide MftA containing conserved C-terminal residues 
–IDGMCGVY. In the presence of the RRE domain MftB, the RS-SPASM enzyme 
MftC, catalyzes the SAM-dependent oxidative decarboxylation and carbon-carbon 
bond formation on MftA to form  MftA*. The roles of the auxiliary [Fe-S] clusters in 
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MftC catalysis as well as the subsequent steps in the biosynthesis of mycofactocin 
are not known. Here, we have provided additional information regarding the roles 
of the auxiliary clusters in MftC. We showed that MftC contains three [4Fe-4S] 
clusters, all of which are required for catalysis. In addition, we measured the 
midpoint potentials of the clusters to provide insights into the redox flipping 
mechanism of MftC. Furthermore, we reconstituted the activity of MftE and showed 
that it selectively hydrolyzes MftA* to form MftA (1-28) and a 3-amino-5-(4-
hydroxybenzyl)-4,4-dimethylpyrrolidin-2-one, herein referred to as AHDP. From 
this study, we have clarified the misunderstandings surrounding the accurate 
precursor for mycofactocin biosynthesis. Subsequently, we reconstituted the 
activity of MftD and showed that it catalyzes the oxidative deamination of AHDP to 
form an α-keto moiety herein referred to as premycofactocin. Lastly, we measured 
the midpoint potential of premycofactocin to be ~ -255 mV and demonstrated that 
it is used by mycofactocin-associated short chain dehydrogenases for multiple 
catalytic turnover. 
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CHAPTER ONE: INTRODUCTION 
1.1   Natural Products and their Significance 
           Naturally occurring small molecules, herein referred to as natural products 
(NPs), make up a significant portion of the current pharmacopoeia especially 
regarding the treatment of infectious diseases, cancer, immunological disorders 
and hypercholesterolemia (1).  They possess intricate molecular frameworks and 
structural diversities which offer them a range of potent biological activities. Owing 
to this, NPs have been recognized as the richest source of novel compounds with 
complex molecular scaffolds and potential therapeutic applications (2–4). In 
addition, NPs continue to play vital roles in augmenting our understanding of 
biology and chemistry (5–7). Unlike the synthetic compounds used in medicine, 
NPs are distinguished by their structural and functional diversity, thus expanding 
their biologically relevant chemical space (8–11).  As a result, natural products 
remain an invaluable source of inspiration for drug design. Research in the 20th 
century identified several classes of natural products with four groups being the 
most prevalent. These groups include the terpenoids, alkaloids, polyketides, and 
non-ribosomal peptides.  
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Figure 1.1 Representative members of the natural product classes highlighting their 
structural diversity (A) Pachymic acid, a terpenoid with anti-cancer properties (B) Chelerythrine, 
an alkaloid with antibacterial properties (C) Erythromycin, a polyketide used as antibiotics and (D) 
Vancomycin, a non-ribosomal peptide also used as antibiotics 
 
           Terpenoids, also referred to as isoprenoids constitute the largest class of 
natural products with diverse structures and potent biological activities (12–14). 
The majority of terpenoids are of plant origin and are composed of multicyclic 
structures with oxygen-containing functional groups (12, 15, 16). Terpenoids are 
involved in a plethora of biologically relevant activities such as cell membrane 
formation, intracellular electron transport (17), regulation of cell growth and 
defense (18), and   anti-cancer drugs (19) (Figure 1.1A). They are biosynthesized 
from two universal five-carbon building blocks: isopentyl diphosphate (IPP) and its 
isomer dimethylallyl diphosphate (DMAPP) (14, 18, 20). Members of this class of 
natural products include monoterpenoids, diterpenoids, triterpenoids and 
tetraterpenoids (13, 15, 19, 21).  
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           Alkaloids are another large class of natural products containing basic 
nitrogen atoms (22) (Figure 1.1B). They are produced by a large variety of 
organisms including bacteria, fungi, plants and animals. They  are biosynthesized 
from complex pathways involving unique building blocks and a number of 
biosynthetic approaches (23). Members of this class are classified based on their 
biosynthetic precursor and heterocyclic ring systems and they include indoles, 
piperidines, tropanes, purines, pyrrolizidines, imidazole, quinolozidine, 
isoquinoline and pyrrolidine (24–26). Due to the extreme toxicity of alkaloids, they 
are mostly involved in the survival of the producing organism by exerting lethal 
effects on others. For instance, alkaloid-producing plants use alkaloids as a 
defense mechanism to ensure survival against microorganisms and herbivores 
(24).  In spite of the high toxicity of alkaloids, this class of NPs has marked 
therapeutic effects in humans when used in small quantities. As a result, alkaloids 
are only used in medicine for their analgesic, antispasmodic and bactericidal 
effects as well as chemical transmitters in the nervous system (24, 25, 27, 28).  
           Polyketides (PK) belong to a structurally diverse class of natural products 
with broad range of pharmacological activities. Their structures are composed of 
highly oxygenated ring systems biosynthesized by multi-enzyme complexes 
referred to as polyketide synthases (PKS).  Polyketides display a broad range of 
potent antibacterial activities. For example, erythromycin, a macrolide antibiotic, is 
used to treat a number of respiratory tract and skin infections as well as sexually 
transmitted infections such as chlamydia and syphilis (29–33) (Figure 1.1C). The 
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standard biosynthetic model of polyketides involves the assembly of activated 
simple carboxylic acid precursor peptides such as malonyl-CoA on PKS through a 
stepwise condensation reaction (30, 31, 33, 34).  Despite having three universal 
catalytic domains (ketosynthase, acyl transferase and acyl carrier protein) PKS are 
classified into two groups based on their similarity to fatty acid synthases : type I 
and the type II PKS, (35). Type I PKS are multifunctional enzymes that are 
organized into modules. Each module possess a discrete set of noniteratively 
acting activities and catalyze only a single cycle of chain elongation during the 
biosynthesis of polyketides (29–32). The type II on the other hand carry only a 
single set of iteratively acting activities and can catalyze several cycles of the chain 
elongation of polyketides (31, 32, 36, 37).   
           Non-ribosomal peptides are another diverse class of secondary metabolites 
with peculiar structures and pharmacological activities. This class of natural 
products is of profound interest because of its bioengineerability to generate new 
drugs with potent biological activities (38–40). The biological properties of non-
ribosomal peptides can range from antibacterial e.g. vancomycin (41), 
immunosuppressive e.g. cyclosporin (42), cytostatic e.g. epothilones A and B (41), 
toxins e.g. thaxtomin  (43) to iron chelators e.g. vibriobactin (44) (Figure 1.1D). The 
biosynthesis of non-ribosomal peptides is carried out by large modular 
multifunctional enzyme complexes with astonishing molecular weights called non-
ribosomal peptide synthetases (42). Within each enzyme complex, there are 
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several modules and each one is responsible for the incorporation of a single 
building block into the final structure of the polypeptide (38–40, 42, 45).  
Although historically only four classes of NPs have been recognized, genome 
sequencing efforts by research scientists in the beginning of the 21st century have 
led to the discovery of a new class of natural products. This class of natural 
products is peptide based and is of ribosomal origin and called Ribosomally 
synthesized and Post translationally modified peptides (RiPPs).       
 
1.2 Ribosomally Synthesized and Post-Translationally Modified 
Peptides (RiPPs) 
           RiPPs are a growing class of natural products that have garnered significant 
attention over the past decade due to their unique biosynthetic pathways and 
tailoring enzymes (46–50). Unlike polyketide synthases (PKS) and non-ribosomal 
peptide synthases (NRPS) which utilize large multi-modular enzyme complexes to 
incorporate unnatural amino acids into the backbone of their natural products (29, 
34, 36, 38–40, 51), RiPPs are derived from genetically encoded precursor 
peptides.  These precursor peptides undergo extensive chemical modifications by 
dedicated post translational modification (PTM) enzymes to achieve similar 
degrees of chemical diversities (47, 49, 50, 52) (Figure 1.2). RiPPs are of 
ribosomal origin and are produced in all three domains of life.  
           A single property of RiPPs that sets them apart from polyketides and non-
ribosomal peptides is their remarkable biosynthetic malleability. This feature 
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enables RiPPs pathways to be genetically engineered to produce new-to-nature 
compounds with higher potency and bioavailability (50), thus expanding the 
biologically relevant chemical space of RiPPs. Owing to this, RiPPs are fertile 
grounds for exploring molecular scaffolds and chemistries that are useful for 
chemotherapeutic applications (52, 53). The biological activities possessed by 
RiPPs are vast, ranging from anti-viral (54), anti-fungal (55), antibiotic (56), anti-
cancer (57), quorum sensing molecules (58, 59), and redox cofactors (60–63) 
(Figure 1.2), to name a few. 
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Figure 1.2 Classical examples of RiPP natural products highlighting their structural 
diversities and biological activities.  (A) The Class III lanthipeptide Labryrinthopeptin A1 with 
anti-viral properties (B) Streptide involved in bacterial cell communication (C) The redox cofactor 
Pyrroloquinoline quinone (PPQ) (D) The thiopeptide Thiomuracin A with potent antibacterial 
properties. 
 
           The biosynthesis of RiPPs typically commences with the ribosomal 
production of the genetically encoded precursor peptide (Figure 1.3 middle row). 
This precursor peptide can house up to three domains: the leader sequence, the 
core sequence and the follower sequence (47). The leader sequence primarily 
serves as a recognition motif for the cognate biosynthetic machinery while the core 
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sequence undergoes extensive chemical transformations and is incorporated into 
the final RiPP product (64). The follower sequence is not strictly conserved and if 
the precursor peptide has any, it often plays the role of the leader peptide (Figure 
1.3 middle row).  Upon translation and substrate engagement, the core sequence 
is extensively modified by post-translational modification (PTM) enzymes and the 
leader peptide is subsequently removed by proteolysis to allow for the maturation 
of the modified core peptide into the final natural product (Figure 1.3 bottom row). 
The PTMs impacted on these peptides endow them with non-proteinogenic 
structures that are not directly accessible by ribosomal or modular synthesis. The 
functionalized RiPP product becomes more conformationally restrained allowing 
for better target recognition, increased metabolic and chemical stability as well as 
increased chemical functionality (47). RiPPs are grouped into different subfamilies 
based on their biosynthetic machinery and structural characteristics and these 
include  sactipeptides, lanthipeptides, thiopeptides, cyanobactins, 
methanobactins, bottromycins, streptides among others (47, 49). Sactipeptides 
can boast of potent antibacterial properties and their biosynthesis involve unique 
chemistries. Streptides are quorum sensing molecules involved in bacterial cell 
communication and possess peculiar biosynthetic machineries. For the purpose of 
this dissertation, only the Sactipeptide and streptide subfamily of RiPPs will be 
discussed. 
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Figure 1.3 Graphical representation of a typical RiPP biosynthesis. (Top row) Typical gene 
organization of a RiPP biosynthetic pathway. (Middle row) Translation of the precursor peptide 
together with the RiPP biosynthetic machinery. (Bottom row) Extensive chemical modifications are 
made to the core sequence of the precursor peptide to form the mature RiPP product. 
 
 
1.2.1 Sactipeptides             
           Sactipeptides are a diverse family of RiPPs natural products that possess 
potent antibacterial, spermicidal and hemolytic properties (65–71). They are 
characterized by a distinct intramolecular thioether bond that crosslinks the sulfur 
atom of a cysteine residue to the alpha carbon of an acceptor amino acid, hence 
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the name sactipeptides. The thioether or sactionine linkages found in sactipeptides 
differ from those found in the well-characterized lanthipeptides, such as nisin. For 
instance, in lanthipeptide biosynthesis, the thioether crosslinks are formed 
between a sulfhydryl group of a cysteine residue and dehydrated side chains of 
threonine or serine residue on the precursor peptide through a Michael-like 
nucleophilic addition. The maturation of sactipeptides on the other hand involve a 
distinct group of enzymes called synthetases which install a thioether crosslink 
between a cysteine residue and an acceptor amino acid on their precursor peptide. 
Another difference between lanthipeptide and sactipeptide thioether linkages is 
that the thioether crosslinks in sactipeptides occur through a radical-mediated 
pathway involving a net two-electron oxidation of the precursor peptide whereas 
those found in lanthipeptides occur through a two-step redox neutral reaction 
mechanisms (72–74). Several subfamilies of sactipeptides have been 
characterized till date and they include Subtilosin A from Bacillus subtilis (Figure 
1.4A), thurincin H from Bacillus thuringiensis (Figure 1.4B), sporulation killing 
factor from Bacillus subtilis (Figure 1.4C), and the two-component thuricin CD from 
Bacillus thuringiensis (Figure 1.4D).  The sactisynthases AlbA, ThnB, SkfB and 
Trn-α/β  are responsible for the installation of S-Cα thioether bonds during the 
maturation of subtilosin A, thurincin H and sporulation killing factor and thuricin CD 
respectively (66, 72, 75–79).  Recently, another subfamily, Huazacin from Bacillus 
thuringiensis serovar huazhongensis was identified and shown to also contain a 
sulfur to alpha carbon thioether crosslink installed by the sactisynthases HuaB and 
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HuaC (80, 81) (Error! Reference source not found. E).  Elegant bioinformatic 
work by Haft and Basu in 2011 identified another subfamily of the sactipeptides. 
This subfamily contains a variable N-terminal domain and a conserved C-terminal 
domain and it is characterized by the presence of a six cysteines in a forty-five 
residue (SCIFF) motif (82). Notable members include freyrasin from Paenibacillus 
polymyxa (Figure 1.4F), thermocellum (Cte) from Clostridium thermocellum 
(Figure 1.4G) and the SCIFF peptide from Tte1186a from Caldanaerobacter 
subterraneus subsp. tengcongensis MB4 (Figure 1.4H) (74, 81, 83). Tte1186 was 
the first sactisynthase from this subfamily to be characterized. It installs a S-Cα 
thioether crosslink on the precursor peptide Tte1186a.  
           A recent hallmark publication by the Mitchell lab demonstrated that not all 
members of the SCIFF subfamily possess S-Cα thioether crosslinks as previously 
proposed. For example, the radical SAM enzyme, CteB from Clostridium 
thermocellum was found to install an S-Cγ thioether crosslink on its precursor 
peptide, CteA during the maturation of thermocellum. In addition, the radical SAM 
enzyme PapB from Paenibacillus polymyxa was also found to install S-Cβ 
thioether crosslinks on its precursor peptide papA during the maturation of 
freyrasin (84). This interesting finding led the Mitchell lab to the proposal of a more 
appropriate nomenclature, a radical non-α thioether peptides (ranthipeptides) for 
this subfamily to structurally and biosynthetically distinguish them from the 
canonical sactipeptides (81).  
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Figure 1.4 Gene scheme of several RiPP biosynthetic gene clusters involved in the 
biosynthesis of ranthipeptides and sactipeptides.  (Left column) Different species containing 
biosynthetic genes encoding the precursor peptides (cyan), radical SAM enzymes (red) responsible 
for installing S-Cα, S-Cβ and S-Cγ thioether bonds, peptidases (blue) responsible for cleaving the 
leader peptide and transporters (green). (Right column) Sactisynthase and ranthisynthase modified 
precursor peptide from each biosynthetic cluster highlighting the leader peptide sequence (pink) 
and the mature RiPP product (blank). The thioether linkages formed between the sulfur atom of a 
cysteine residue and the Cα, Cβ, or Cγ of the acceptor residue are shown in red. Disulfide bonds 
are shown in blue. 
 
 
 
 
           The biosynthesis of sactipeptides and ranthipeptides begins with the leader 
peptide-dependent post translational modification of the precursor peptide core by 
sactisynthases. These sactisynthases house an N-terminal [4Fe-4S] radical SAM 
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cluster and a C-terminal extension that can house up to two additional [4Fe-4S] 
clusters (72, 83, 85). During sactionine linkage formation, the radical SAM cluster 
is used to homolytically cleave SAM to generate a highly reactive 5’-
deoxyadenosine radical. This radical abstracts a hydrogen atom from the substrate 
to form a substrate radical and 5’-deoxyadenosine. The substrate radical further 
undergoes an oxidation to form a more stable ketoimine intermediate (74) (Figure 
1.5). Subsequent stereoselective intramolecular nucleophilic attack of a cysteine 
thiol on the unsaturated ketoimine via conjugate addition mechanism yields the 
corresponding crosslinked thioether bonds in the precursor peptide. 
 
 
 14 
 
 
Figure 1.5 General reaction mechanism proposed for the biosynthesis of sactipeptides and 
ranthipeptides.  This mechanism involves the abstraction of a hydrogen atom from the αβγ 
position of the precursor peptide. This is followed by the loss of an electron to form a ketoimine 
intermediate. Subsequent nucleophilic attack by a vicinal thiol on the ketoimine results in the 
formation of the matured RiPP product. 
 
1.2.2 Streptides   
            Another family of RiPPs that has attracted significant attention due to their 
interesting biological activities is the Streptide family. Streptide is a 9-mer peptide 
that was first identified and characterized in 2007 by Ibrahim et al. (58). Streptides 
are pheromones produced by a number of pathogenic bacteria including 
Streptococcus thermophilus, and contain lysine to tryptophan crosslink in their 
peptide backbone to form an N-terminal macrocyclic structure (58, 59, 86–89).  
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They function as quorum sensing molecules in processes such as cell 
communication between a number of Streptococci (58, 59). The Streptide 
biosynthetic machinery is composed of the genes strABC which encode the 
precursor peptide StrA, the radical S-adenosylmethionine (SAM) enzyme StrB and 
the protease/transporter StrC respectively (88, 89) (Figure 1.6A).  
           The biosynthesis of Streptide commences with the ribosomal production of 
the genetically encoded precursor peptide StrA containing the conserved motif 
KGDGW (90). Following the reductive cleavage of SAM by StrB and the 
subsequent formation of the 5’-deoxyadenosine radical, a hydrogen atom is 
abstracted from the Cβ of Lys 16 on the precursor peptide StrA to form a lysyl 
radical and 5’-deoxyadenosine (Figure 1.6B). In the presence of a base, the lysyl 
radical then attacks the 3-position of the indole ring of Trp 20 to form an 
intramolecular carbon-carbon crosslink followed by re-aromatization of the ring 
and an electron transfer into one of auxiliary clusters. The modified core is then 
hydrolyzed from the rest of the precursor by the protease/transporter StrC to 
liberate the matured biological active product, Streptide (Figure 1.6B). The 
successful maturation of RiPPs natural products is contingent on the RiPP 
biosynthetic machinery, working independently in a sequential manner. One of the 
most critical components of this biosynthetic machinery is the class of radical SAM 
enzymes.   
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Figure 1.6 Streptide biosynthesis. (A) Streptide biosynthetic gene cluster activated by shp/rgg 
quorum sensing system and a condensed representation of the biosynthesis of Streptide. (B) 
Detailed reaction mechanism for Lys-to-Trp crosslink on the precursor peptide StrA, catalyzed by 
StrB during Streptide biosynthesis.  
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1.3 Structural Architecture of radical S-adenosylmethionine (RS) 
enzymes 
           Of the post-translational modification enzymes involved in the biosynthesis 
of RiPP natural products, one class has garnered enormous attention over the 
years. This is the so called class of radical SAM (RS) enzymes which are well 
known for their ability to anaerobically catalyze chemically difficult transformations 
(91, 92).  These enzymes utilize a [4Fe−4S] cluster and S-adenosylmethionine to 
initiate an array of radical reactions via generation of a highly potent 5′-
deoxyadenosyl radical intermediate. Structurally, RS enzymes can house up to 
three domains, all of which are required for catalysis. The first domain is an N-
terminal extension that is used for binding substrate or cofactors. Following the N-
terminal extension is the radical SAM domain, catalytic core that houses an active 
site [4Fe-4S] cluster. The third domain is a functionalized C-terminal extension for 
housing additional cofactors. 
 
1.3.1 N-terminal Extensions of RS enzymes. 
           The N-terminal extensions of radical SAM enzymes adopt a typical winged-
helix-turn (wHTH) motif (Figure 1.7). This was first observed in the crystal 
structures of the RiPP biosynthetic enzymes LynD and NisB where the leader 
sequences of their precursor peptides were found bound by a (wHTH) motif (93, 
94). Subsequent bioinformatic analysis by the Mitchell group in 2015 also identified 
another conserved motif linking the homologous wHTH motifs in NisB and LynD 
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(95). This motif was found to be conserved among a number of prokaryotic RiPP 
classes and they are either fused to the RS enzyme or exist separately of the RS 
enzyme (93–96). Sequence homology alignment of wHTH motif in LynD and NisB 
revealed its structural homology to the protein PqqD (95) (Figure 1.7). PqqD is a 
small peptide chaperone involved in the biosynthesis of the peptide-derived redox 
cofactor pyrroloquinoline quinone (PQQ) (96). This PqqD-like domain was also 
previously identified in AlbA from subtilosin biosynthesis, however its exact role in 
RiPP biosynthesis remained largely enigmatic (47). In the biosynthesis of PQQ, 
the radical SAM enzyme PqqE was found to only bind to and modify the precursor 
peptide PqqA in the presence of the peptide chaperone PqqD (96). An alternate 
scenario was also observed in the biosynthesis of mycofactocin where the radical 
SAM enzyme MftC only bound to, and modified the precursor peptide MftA in the 
presence of the peptide chaperone MftB (97–99).  The crystal structure of MftB is 
yet to be determined, however, sequence homology alignment revealed it 
possesses high similarity to PqqD. Additional bioinformatic analysis also 
demonstrated that these motifs were routinely found in RiPP biosynthetic proteins 
but absent in homologs not involved in processing of RiPPs. A more compelling 
evidence came from the finding that RiPP enzymes which act after the cleavage 
of the leader sequence from the precursor peptide lacked this motif (95). The 
aggregated bioinformatic data led the Mitchell group to propose that the PqqD-like 
domains associated with peptide modifying enzymes are used to recognize and 
bind the leader sequence of RiPP precursor peptides. This domain was therefore 
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named RiPP precursor peptide recognition element (RRE) to highlight its role in 
the biosynthesis of RiPPs (95). This motif is composed of three antiparallel 
consecutive β-strands adjoining three consecutive α-helices (Figure 1.7) 
 
 
Figure 1.7 Crystal structure of the RRE domain of LynD (PDBID 4V1T).  The three antiparallel 
β-strands and three α-helices adopt a winged-helix-turn-helix motif and constitute the conserved 
RiPP precursor peptide recognition element (RRE).  
 
1.3.2 Radical SAM domain of RS enzymes 
           The radical SAM domain is responsible for binding SAM and the generation 
of the 5’-deoxyadenosine radical. This domain is comprised of a six (β/α) motifs 
arranged in a fashion that is reminiscent of triose-phosphate isomerase (TIM) 
barrel fold.  The six α-helices make up the outside of the partial barrel and the six 
β-strands form the inner surface of the TIM barrel (100–102) (Figure 1.8). Although 
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some radical SAM enzymes are composed of the complete (β/α)8 TIM barrel fold 
as found in HydE (103), BioB (104, 105) and ThiC (106), most of them have the 
partial TIM barrel fold. Whereas the partial TIM barrel fold is comprised of six 
repeating β/α motifs, the complete TIM barrel fold is composed of eight repeating 
β/α motifs. There are four distinct motifs within this domain that are responsible for 
coordinating SAM. The most conserved and important among them is the 
CX3CXɸC (where ɸ is an aromatic residue) motif which binds the [4Fe-4S] cluster 
responsible for initiating radical chemistry (Figure 1.8). The three cysteines of this 
motif reside on the loop linking the β1 strand to the α1 strand, referred to as the 
cluster-binding loop and are responsible for ligating three of the irons from the 
[4Fe-4S] cluster. The fourth iron, termed the “unique iron” is ligated to the 
carboxylate and amino group of SAM in a bidentate fashion (Figure 1.8). Another 
motif, which is not strictly conserved is the Gly-Gly-Glu motif named after the 
residues in the radical SAM enzymes MoaA and pyruvate formate lyase activating 
enzyme. In these enzymes, the Gly-Gly-Glu motif resides at C-terminal end of the 
β2 strand in the radical SAM core and forms hydrogen bonds with the amino group 
of SAM molecule. This interaction allows the bidentate ligation of the carboxylate 
and amino groups of SAM to the unique iron of the [4Fe-4S] cluster (101), thus 
orienting the methionyl moiety of SAM. On the β4 strand of the radical SAM core 
is another motif termed “ribose motif (Figure 1.8). Residues on this motif form 
hydrogen bonds with both the 2’ and 3’ hydroxyl groups of the ribose moiety on 
SAM and orient the 5’-deoxyadeonsyl radical towards the substrate for hydrogen 
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atom abstraction during catalysis (107). The last motif which is only partially 
conserved within this domain is the “GXIXGXXE motif” named after the 
corresponding sequence in BioB (104, 105), located on β5 strand. This motif 
provides hydrophobic interactions with the adenine ring of SAM (Figure 1.8). Taken 
together, all four motifs work in tandem to ensure adequate positioning of SAM for 
homolytic cleavage, radical generation and subsequent hydrogen abstraction from 
the substrate during radical SAM catalysis. 
 
Figure 1.8 Radical SAM domain of anSME from Clostridium perfringens (PDB ID 4K37). The 
typical partial (β/α)6 TIM barrel fold of the radical SAM core. Shown are the CX3CXɸC motif (yellow)  
for binding [4Fe-4S] cluster (yellow sticks), and the bidentate coordination of the unique iron to 
SAM (orange/blue sticks), the GGE motif (magenta), the ribose motif and the GXIIGXXE motif, all 
of which are necessary for orientation and cleavage of SAM during catalysis. 
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           The canonical function of the radical SAM domain is the generation of a 
radical using a [4Fe-4S] cluster and SAM. This is a two-step process and requires 
SAM to be placed in the immediate vicinity of the [4Fe-4S] cluster to directly 
coordinate the cluster and allow for electron transfer.  The first step in the radical 
generation is the reduction of the [4Fe-4S] cluster from the resting +2 oxidation 
state to the active +1 oxidation state. This is facilitated by the presence of an 
electron donor such as flavodoxin/flavodoxin reductase, a physiological reductant 
or sodium dithionite (DTH), a non-physiological reductant (108). The final step is 
the cleavage of SAM. This step involves the transfer of an electron from the 
reduced [4Fe-4S] cluster to the sulfonium antibonding orbital of SAM through an 
inner sphere electron transfer mechanism (109), resulting in the homolytic 
cleavage of SAM to form methionine and a highly potent 5’-deoxyadenosine radical 
(Figure 1.9). In a substrate coupled SAM cleavage, the generated 5’-
deoxyadeonsine radical abstracts a hydrogen atom from the precursor peptide, 
thus priming the substrate for the formation of desired chemical transformations. 
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Figure 1.9 Proposed reaction mechanism of SAM cleavage.  The reductive cleavage of SAM 
in RS enzymes showing an electron transfer from the reduced [4Fe-4S] cluster into the antibonding 
orbital of SAM to yield the 5'-dA radical and methionine.  
 
1.3.3 C-terminal extensions of RS enzymes 
           On top of the RRE domain and the radical SAM domain, some RS enzymes 
have C-terminal extensions that are functionalized for binding substrates or other 
cofactors (83, 85, 110, 111). Radical SAM enzymes with functionalized C-terminal 
extensions are classified as either RS-TWITCH enzymes or RS-SPASM enzymes. 
The RS-TWITCH enzymes harbor one additional [Fe-S] cluster in their C-terminal 
extensions while the RS-SPASM enzymes house two additional [Fe-S] clusters in 
their C-terminal extensions (83, 101, 110, 112–115) (Figure 1.10).  The C-terminal 
TWITCH domain is an abridged C-terminal SPASM domain which typically 
contains a conserved three/four cysteine motif for coordinating one additional [Fe-
S] cluster.  Examples of such protein fold can be found in BtrN (112) (Figure 1.10A) 
and MoaA (116) (Figure 1.10B) and recently characterized enzyme SkfB (85). 
 24 
 
Unlike BtrN and MoaA, both of which contain a [4Fe-4S] cluster as the Aux I, SkfB 
contains a [2Fe-2S] cluster as the Aux I (101). The Aux I cluster in MoaA has an 
open coordination site for substrate binding (Figure 1.10B).  The protein fold and 
functions of SPASM RS enzymes are described in detail below. 
 
 
Figure 1.10 Comparison of TWITCH and SPASM domains of RS enzymes (A) The TWITCH 
domain of BtrN showing four cysteines for coordinating the Aux I cluster. (B) The TWITCH domain 
of MoaA showing three cysteines for the Aux I cluster with an open coordination site for substrate 
binding. (C) SPASM domain of anSME showing eight cysteines for coordinating Aux I and Aux II 
clusters. (D) SPASM domain of SuiB harboring two additional [4Fe-4S] clusters. ( E) SPASM 
domain of PqqE showing the eight cysteine residues that are involved in coordinating the two 
auxiliary [Fe-S] clusters. (F) The functionalized C-terminal extension of CteB containing two 
auxiliary clusters with an open coordination site on the Aux I cluster for substrate binding. 
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1.4 RS-SPASM Enzymes 
           Bioinformatic studies by Haft and Basu in 2011 identified a domain in the 
C-terminal region of a subset of radical SAM enzyme class designated as 
TIGR08045 (82). This domain houses two additional cofactors suggesting its 
probable involvement in the post-translational modification of the corresponding 
precursor peptides. The cluster proximal to the RS-cluster is annotated as the Aux 
I cluster, and the distal cluster is annotated as the Aux II cluster (Figure 1.10 and 
Figure 1.11). The functionalized C-terminal extensions of these enzymes have a 
conserved seven cysteine CX9-15GXC-gap-CX2CX5CX3C-gap-C motif (83, 110, 
114, 117, 118) (Figure 1.11). This motif is typically used for binding the two 
auxiliary [4Fe-4S] clusters, leaving a unique iron with an open coordination site for 
substrate binding (82, 83, 113) (Figure 1.10F). However, structural 
characterization of anSME, PqqE and SuiB showed full ligation of both Aux I and 
Aux II clusters by cysteine residues (110, 117) (Figure 1.10C, D and E). Unlike 
anSME and SuiB, both of which contains a [4Fe-4S] cluster in their Aux I site, PqqE 
contains a [2Fe-2S] cluster in its Aux I site (119, 120). The functions of these 
auxiliary clusters remain to be determined. However, they are proposed to play 
important catalytic roles such as binding and positioning of the substrate to the 
radical SAM cluster as found in CteB (83) and AlbA (76), or act as an electron 
shuttle for the controlled transfer of unpaired electrons out of the enzyme’s active 
site during the oxidation of the substrate radical intermediate (113, 121). The 
functionalized C-terminal extensions of RS-SPASM proteins highlight both the 
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diversity of reactions catalyzed by these enzymes as well as the range of functions 
of the iron-sulfur clusters. 
 
Figure 1.11 Architecture of the SPASM domain of SuiB from Streptococcus suis 
(PDB:5Q1V).  Highlighted in yellow are the cysteine residues in the CX9-15GXC-gap-CX2CX5CX3C-
gap-C motif used to coordinate two Auxiliary [4Fe-4S] clusters. The iron sulfur clusters are 
represented in sticks. 
 
 
         
           The name “SPASM” was coined for this subfamily of radical SAM enzymes 
as an abbreviation from the biochemically characterized founding members AlbA, 
PqqE, anSME and MftC which are radical SAM enzymes involved in the maturation 
of Subtilosin A, Pyrroloquinoline quinine, Anerobic sulfatase and Mycofactocin 
respectively. Anaerobic sulfatase maturation enzyme, AtsB is the first structurally 
characterized RS-SPASM protein and it has been shown to catalyze the two-step 
formal electron oxidation of a critical serine or cysteine residue into a Cα-
formylglycine, an in situ arylsulfatase cofactor required for the activity of AstA (117, 
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122, 123) (Figure 1.12A). The second member of this subfamily to be chemically 
characterized is AlbA, even though its crystal structure is yet to be solved. AlbA 
catalyzes the formation of sulfur to alpha carbon thioether bond (sactionine 
linkage) on its precursor peptide SboA during the maturation of the antibacterial 
peptide subtilosin A (72, 76) (Figure 1.12B). PqqE and MftC are both SPASM 
proteins involved in the biosynthesis of the peptide derived redox cofactors PQQ 
and Mycofactocin respectively. PqqE catalyzes the formation of a carbon-carbon 
bond between a glutamate and a tyrosine residue on its precursor peptide PqqA 
during the biosynthesis of PQQ (Figure 1.12C) while MftC catalyzes the oxidative 
decarboxylation of the C-terminal tyrosine residue followed by a carbon-carbon 
bond formation between the penultimate valine and the decarboxylated tyrosine 
during the biosynthesis of mycofactocin( Figure 1.12D) (97–99, 124).   
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Figure 1.12 Reactions catalyzed by SPASM-domain radical SAM enzymes.  (A) anSME 
(anaerobic Sulfatase-Maturating Enzyme: Cysteine or serine oxidation into Cα-formylglycine), (B) 
AlbA (Subtilosin A biosynthesis: S-Cα thioether bond formation), (C) PqqE (PQQ biosynthesis: C-
C bond formation) (D) MftC (Mycofactocin biosynthesis: C-C bond formation). 
 29 
 
           More recently, the crystal structure of the first thioether bond forming 
SPASM radical SAM enzyme, CteB was determined (83). It was shown that its Aux 
I cluster is ligated by three cysteines leaving an open coordination site for substrate 
binding (Figure 1.10F and Figure 1.13A). CteB installs an sulfur to gamma carbon 
thioether bond on its precursor peptide CteA during the maturation of thermocellum 
(81, 83). Another RS-SPASM protein whose structure was recently solved is SuiB. 
The crystal structure of SuiB revealed the presence of two [4Fe-4S] clusters within 
its SPASM domain, both of which are fully ligated by four cysteine residues (110) 
(Figure 1.10D and Figure 1.13B). SuiB catalyzes the carbon-carbon crosslink 
formation between lysine and tryptophan residues on its precursor peptide SuiB 
during the maturation of the quorum sensing molecule Streptide (Figure 1.6).  
 
Figure 1.13 Complete crystal structures of the RS SPASM proteins.  (A) CteB from Clostridium 
thermocellum (PDB: 5WHY) and (B) SuiB from Streptococcus suis (PDB:5Q1V). The N-terminal 
RRE region used for substrate recognition is colored green. The Radical SAM domain (blue) forms 
a partial TIM-barrel fold and houses the RS-[4Fe-4S] cluster. The C-terminal SPASM domain 
(orange) harbors two additional [4Fe-4S] clusters. The bridging region (red) which is unique to SuiB 
connects the radical SAM domain to the SPASM domain. 
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 1.5 Peptide-derived Redox Cofactors            
            Peptide-derived redox cofactors are genetically encoded redox cofactors 
that are derived from post translational modification of the amino acid side chains 
within either a precursor peptide or a protein (125, 126). The best characterized 
peptide-derived redox cofactors are those that originate from tyrosine (127) 
and tryptophan (128) residues. Currently, there are five known peptide-derived 
redox cofactors and they include 2,4,5-trihydroxyphenylalanine quinone (TPQ), 
lysyl-tyrosine quinone (LTQ), tryptophan-tryptophylquinone (TTQ), cysteine-
tryptophylquinone (CTQ),   and pyrroloquinoline quinone (PQQ) (Figure 1.14). 
These quinocofactors participate in key biochemical processes in either 
prokaryotic and or eukaryotic organisms. For example, TPQ, which is also known 
as topaquinone spans both domains of life and functions as the prosthetic group 
of copper-containing amine oxidases (61, 127, 129). LTQ is present as a prosthetic 
group in lysyl oxidase, an enzyme involved in collagen and elastin production in 
mammals (61, 130).  TTQ is used as the prosthetic group of aromatic amine 
dehydrogenases and methylamine dehydrogenases (126). CTQ is a protein-
derived redox cofactor which functions as a prosthetic group in bacterial 
quinohemoprotein amine dehydrogenases(131, 132). PQQ is the prosthetic group 
of methanol and glucose dehydrogenases that catalyze the oxidation of alcohols 
and aldose sugars respectively (133–137). While the overall structures of these 
cofactors vary significantly, they do share a common feature – they are quinone 
based (Figure 1.14).  
 31 
 
 
Figure 1.14 Structures of known peptide-derived quinocofactors.  2,4,5-
trihydroxyphenylalanine quinone (TPQ), lysyl-tyrosine quinone (LTQ), tryptophan-
tryptophylquinone (TTQ), cysteine-tryptophylquinone (CTQ), and pyrroloquinoline quinone (PQQ) 
 
 
 
              Of the five described peptide-derived quinocofactors, all except for PQQ 
are synthesized in situ of their functional enzymes. For instance, TPQ, LTQ, TTQ 
and CTQ are derived from tryptophan or tyrosine side chains of the enzymes that 
require them and found covalently bound to these enzymes as prosthetic groups 
(128, 131, 132, 138–140). PQQ on the other hand is derived from a RiPP precursor 
peptide after extensive chemical modification by dedicated posttranslational 
modification enzymes that are colocalized on the same operon as the precursor 
peptide. Because PQQ is the first known RiPP-derived redox cofactor, the 
following section focuses on its functions and biosynthesis. 
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1.6 Pyrroloquinoline quinone (PQQ) 
1.6.1 Functions of PQQ 
            PQQ is a low molecular weight redox cofactor utilized by a variety of gram-
negative bacteria. The majority of these bacteria catalyze oxidation of alcohols and 
aldose sugars in the periplasmic space via non-glycolytic pathways to produce 
cellular adenosine triphosphate (ATP) (137, 141, 142). These enzymes reduce the 
orthoquinone form of PQQ to its quinol form with the concomitant oxidation of their 
corresponding substrates (134, 141, 142) (Figure 1.15). The reduced PQQ is then 
re-oxidized by the release of two electrons (Figure 1.15) which are in turn used to 
reduce ubiquinone to produce ATP (142). The midpoint potential of PQQ was 
found to be -240 mV at pH 13 (143), making it more oxidative than nicotinamide 
adenine dinucleotide (NAD+) and flavin mononucleotide (FMN) (144, 145).  
However, this midpoint potential is comparable to that of ubiquinone which is +66 
mV at pH 7 (146, 147). Unlike most bacteria, PQQ is scarcely found in the tissues 
of animals due to their inability to biosynthesize it, and thus acquire PQQ from their 
diet. In mammals, the exact role of PQQ is yet to be fully understood however, 
some studies suggest its involvement in fertility and mitochondrial biogenesis (134, 
148, 149). 
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Figure 1.15 Function of PQQ in methanol dehydrogenases.  Methanol dehydrogenases use 
PQQ to oxidize methanol to formaldehyde and in the process reduces PQQ to PQQH2. The 
electrons in PQQH2 are subsequently shuttled into the electron transport chain to generate ATP. 
 
 
1.6.2 Biosynthesis of PQQ           
           PQQ is biosynthesized from the evolutionarily conserved glutamate and 
tyrosine side chains within the ribosomally produced precursor peptide PqqA. This 
is achieved through the dedicated actions of the products of five conserved genes 
in the PQQ biosynthetic gene cluster (150–153).  These conserved genes 
annotated as pqqABCDF/G have been found in over 100 species of bacteria (47, 
141). In all cases, pqqA encodes for the short precursor peptide, typically 20-30 
amino acids in length containing  conserved glutamate and tyrosine from which 
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PQQ is derived (141, 152) (Figure 1.16A). The genes pqqB and pqqC encode the 
hydrolase PqqB and cofactorless oxidase PqqC respectively(141, 154–156). The 
remaining genes pqqDEF/G encode the REE domain PqqD, the radical SAM 
enzyme PqqE and the peptidase PqqF/G respectively (96, 141, 154, 157, 158) 
(Figure 1.16A). PQQ biosynthesis commences with the ribosomal production of 
PqqA containing an N-terminal leader sequence and C-terminal core with 
conserved glutamate and tyrosine residues. The first step of the posttranslational 
modification occurs when the peptide chaperone PqqD engages both the leader 
sequence of the precursor peptide and the N-terminal RRE domain of the radical 
SAM enzyme PqqE, bringing both PqqA and PqqE into proximity and orienting the 
core region of PqqA into the active pocket of PqqE. In the presence of the 
physiological reductant flavodoxin/flavodoxin reductase, an electron is transferred 
from the radical SAM [4Fe-4S] cluster into the antibonding orbital of SAM resulting 
in the homolytic cleavage of SAM to form 5’-deoxyadenosine radical and 
methionine. This highly potent radical subsequently abstracts a hydrogen atom 
from the γ-position of the conserved glutamate to form a glutamyl radical and 5’-
deoxyadenosine. The glutamyl radical attacks the phenyl ring of tyrosine followed 
by a subsequent aromatization of the ring in the presence of a base resulting in 
the formation carbon-carbon crosslink between glutamate and tyrosine on the 
PqqA (96, 158) The second step in the biosynthesis of PQQ is the removal of the 
leader peptide to liberate the small molecule for further processing. This step is 
carried out by the two component protease PqqF/G using three molecules of water 
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(157, 159). Other proteases are  believed to be involved in the final hydrolysis step 
of biosynthesis after the removal of the leader peptide by PQQF/G (159). The next 
step is the oxidation of the phenyl ring of tyrosine by the iron-dependent 
hydroxylase PqqB. PqqB catalyzes the insertion of two atoms of oxygen into the 
phenyl ring using iron (II) thus facilitating the spontaneous ring closure of the PqqB 
reaction product to form 3a-(2-amino-2-carboxyethyl)-4,5-dioxo-4,5,6,7,8,9-
hexahydroquinoline-7,9-dicarboxylic acid (AHQQ) (156). Following this is the final 
step in the biosynthesis of PQQ catalyzed by PqqC. PqqC is a  cofactorless 
oxidase that uses molecular oxygen and hydrogen peroxide to catalyze the ring 
closure and an eight-electron oxidation of AHQQ to form PQQ (155, 160) (Figure 
1.16B).       
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Figure 1.16 Condensed representation of PQQ the biosynthetic pathway.  (A) PQQ 
biosynthetic gene cluster from Methylobacterium extorquens AM1. (B) Condensed representation 
of the formation of PQQ from conserved glutamate and tyrosine residues in the PqqA peptide. 
AHQQ is an intermediate that is further modified by the cofactorless oxidase, PqqC, to yield the 
biologically active cofactor PQQ. 
 
 
           Recently, a new and uncharacterized biosynthetic pathway which could 
also encode for a RiPP-derived redox cofactor has been identified. This 
biosynthetic pathway is widely distributed among the Mycobacterium genera and 
shares a striking resemblance to the PQQ cofactor and bacteriocin biosynthesis 
pathways, and thus the putative product of the pathway has been named 
mycofactocin. The focus of this dissertation is on the elucidation of the 
biosynthesis, structure and function of mycofactocin. 
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1.7 Mycofactocin 
1.7.1 Implications of the Mycofactocin Biosynthetic Pathway in 
Mycobacterium tuberculosis. 
           Many species within the Mycobacterium genus are prominent and 
opportunistic pathogens that cause severe skin and lung diseases in humans and 
animals. Notable human pathogenic species include M. ulcerans, the causative 
agent of the debilitating skin disease buruli ulcer, and M. tuberculosis, the 
causative agent of the deadly pulmonary infection tuberculosis (161, 162). 
Tuberculosis is the world’s leading killer of infectious diseases, exceeding the 
human immunodeficiency virus (HIV) and malaria. More than a third of the world’s 
population has been predicted to be infected with tuberculosis (163), with more 
than 1.6 million global deaths annually (164). This scenario has been complicated 
by the fact that many Mycobacteria have become increasingly drug-tolerant,  
resisting the current first-line antibiotics isoniazid and rifampin (165–167).  Taken 
together, there is an urgent need to discover new therapeutic targets for the 
treatment of tuberculosis. This relies on complete understanding of the metabolic 
pathways in Mycobacteria, especially M. tuberculosis. Important physiological 
functions such as those essential for growth and/or survival of M. tuberculosis are 
potential targets for new antimicrobial drugs. A bioinformatic study identified a 
biosynthetic gene cluster that is widely distributed in the Mycobacterial genus and 
present in all strains of M. tuberculosis (168, 169). This biosynthetic gene cluster 
is called the mycofactocin biosynthetic pathway. In addition to the bioinformatic 
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study, a recent pan-genomic analysis of 36 strains of M. tuberculosis revealed that 
the genes of the mycofactocin gene cluster are among the top 5% core genes of 
Mycobacteria (168). This suggests that the genes of the pathway and thereby the 
putative product of the pathway, participate in important physiological processes 
in these organisms. Therefore, a detailed understanding of the biosynthesis and 
function of the product of this pathway will provide meaningful insights into 
chemistry and physiology of these pathogens. This can serve as avenues for the 
development of tuberculosis intervention strategies such as designing of drug 
targets or silencing of important immunomodulatory or virulence genes.  
          Mycofactocin has been proposed through bioinformatic studies to function 
as a redox cofactor. Although there are some in vivo data regarding the essentiality 
of the pathway in M. tuberculosis, the exact physiological function of mycofactocin 
is yet to be determined. In an initial study using transposon site hybridization 
(TraSH), where the genes required for M. tuberculosis survival  were idenitified 
and mutated and the resulting M. tuberculosis mutant strains were recovered on 
mice spleen, mycofactocin genes were found to be nonessential for M. 
tuberculosis survival during infection (170). This finding was further substantiated 
by a transposon sequencing (TnSeq) experiment where the mycofactocin genes 
were found to be nonessential when M. tuberculosis is grown on enriched media 
(171). However, when M. tuberculosis was grown on cholesterol, the mycofactocin 
genes were found to be critical for the growth of the pathogen (172, 173). This 
finding was very significant because the persistence of the pathogen in the host 
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during the latent phase of tuberculosis infection is dependent on its ability to 
mobilize and utilize the host’s cholesterol as carbon source (172–175). This 
unusual ability of M. tuberculosis to catabolize the host’s cholesterol allows it to 
evade the host’s defense mechanism and thereby sustain a persistent infection by 
decreasing the permeability of the cell wall to  antituberculosis drugs such as 
rifampin  (172, 176) (Figure 1.17). In vitro gene expression studies have indicated 
that a number of genes are upregulated and necessary for M. tuberculosis H37Rv 
growth on cholesterol and among these genes are the mycofactocin genes 
Rv0693, Rv0694, Rv0695, and Rv0696  (mftC, mftD, mftE, and mftF, respectively) 
(177). In addition,  the mycofactocin-associated Zn/NAD+ -dependent 
dehydrogenase encoding the gene Rv0761c was found to be also essential for the 
catabolism of cholesterol by M. tuberculosis (170, 178).           
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Figure 1.17 Ability of M. tuberculosis to utilize cholesterol allows it to circumvent the host’s 
defense mechanism and persist within the phagosome.  After internalization, the pathogen 
uses an array of strategies to modulate phagosome maturation. [1] Inhibition of macrophage fusion 
with the lysosome. [2] Inhibition of macrophage acidification. [3] Expression of the virulent Pro-Glu 
repetitive glycine-rich proteins. [4] Retention of cholesterol associated host protein (TACO) to 
prevent bacterial delivery to the lysosome. [5] While in the phagosome, the bacteria are protected 
from reactive oxidative radicals  
 
 
 
               While the role of Mycofactocin in the cholesterol catabolism is not very 
clear (175), these findings suggest that mycofactocin and mycofactocin-associated 
genes might be playing a supporting role in the virulence of M. tuberculosis. In 
support of this idea, recent gene knockout studies by the Kaufmann group have 
indicated that the genes mftA-D and mftF, along with the iron-dependent alcohol 
dehydrogenase msmeg_6242 (TIGR04266), are essential for ethanol assimilation 
in the model organism Mycobacterium smegmatis mc2 155. In addition, the same 
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study demonstrated that disruption of the mycofactocin genes led to imbalance of 
cellular concentrations of NAD+/NADH (179). The results from these studies 
provided for the first time, in vivo evidence that mycofactocin may play a role in 
redox metabolism. A subsequent study by Jain group also demonstrated that the 
genes and the product of the pathway are indispensable for the growth of M. 
smegmatis on methanol as sole carbon source (180).  Collectively, these findings 
suggest that mycofactocin genes and thereby the putative product of the pathway 
play an important role in the survival of M. tuberculosis during tuberculosis 
infection. 
 
1.7.2 Occurrence and Architecture of the Mycofactocin Biosynthetic 
Pathway 
           Mycofactocin is a putative peptide derived redox cofactor derived from the 
actions of the products of six conserved genes, mftABCDEF. The pathway was 
first identified by Haft in 2011 through a bioinformatic study in which the 
sporadically distributed pathway was described (169). The study revealed that the 
gene product MftC, belongs to the RS-SPASM enzyme subfamily (82). Proteins of 
this subfamily are known to chemically modify peptides by installing intramolecular 
carbon-sulfur and carbon-carbon bonds (123, 181). Using the MftC clade as a 
starting point, Haft identified the remaining five mycofactocin genes in immediate 
neighborhood localized around mftC (Figure 1.18). From this bioinformatic study, 
it was shown that the association of mftABCDEF is such that they are either found 
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all together or none at all, implying that they are part of the same biosynthetic 
pathway (169). In addition, Haft also identified other genes within the immediate 
neighborhood of the mycofactocin biosynthetic gene cluster, primarily a variety of 
dehydrogenases. These dehydrogenases, mainly members of TIGR03971, 
TIGR03989, and TIGR04266 families were found to be dependent upon the 
presence of the mycofactocin biosynthetic gene cluster. However, unlike 
mycofactocin genes, these ancillary genes do not share the same strict association 
with the pathway. Instead, they are found in various combinations only when the 
mycofactocin gene cluster is present, suggesting that they are dependent upon the 
product of this pathway, (169, 182).  Significantly, members of the mycofactocin-
associated dehydrogenase families were recently demonstrated to contain 
nonexchangeable NADH that were active in vitro only in the presence of 
nonphysiologically relevant redox mediators (182). In addition to these ancillary 
genes, the bioinformatic study identified also idenitified the gene mftR which is 
annotated as a member of the TetR family of regulators (183).  Proteins within this 
family are single component regulators responsible for the regulation of a wide 
variety of biosynthetic pathways. Taken together, the bioinformatic study suggests 
that the expression of mycofactocin biosynthetic pathway is controlled by the gene 
product of this TetR like regulator denoted as MftR and the product of this pathway 
may be used by the pathway-associated short chain dehydrogenases (Figure 
1.18). 
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Figure 1.18 Gene organization of the mycofactocin biosynthetic pathway.  The mycofactocin 
gene organization (blue) from various species indicates that the genes mftABCDEF are generally 
found together and that mftR (gray) is the regulator of the pathway. Ancillary genes (red), such as 
short-chain dehydrogenases (SDR) and zinc-dependent dehydrogenases (ZnDH) can be found in 
various combinations but are dependent upon the presence of the mycofactocin biosynthetic 
cluster. Additional genes, such as the mycofactocin fadH, are also associated with the pathway but 
for unclear reasons 
 
 
            The mycofactocin biosynthetic pathway is one of the most widely distributed 
RiPP systems in bacteria, however, this distribution is heavily skewed towards the 
Mycobacterial genus. A search of MftC in the Uniprot database, followed by careful 
examination of the gene context of putative homologs, led to the discovery of the 
mycofactocin biosynthetic pathway in 625 unique species and subspecies. Among 
these 625 species are representative members from the Proteobacteria, 
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Chloroflexi, Euryarchaeota and Firmicutes phyla (Figure 15). However, the 
majority of these mycofactocin producing species belong to the Actinobacteria 
phylum. Within this phylum are a number of genera containing significant 
populations of species and subspecies that harbor the requisite mycofactocin 
genes. Notably, the Streptomyces, Geodermatophilus, Nocardia, Nocardiodes, 
Frankia, Pseudonocardia, Rhodococcus and Gordonia genera were found to 
contain 20, 17, 15, 17, 17, 15, 66 and 36 represented species and subspecies 
respectively. Interestingly, about half of all the mycofactocin-producing species 
identified were found to be concentrated in the Mycobacterium genus, with 300 
represented species and subspecies (Figure 1.19). The mycofactocin gene cluster 
was also found to be evenly distributed in the genomes of both slow and rapid 
growing Mycobacteria (184), including human pathogenic variants such as M. 
tuberculosis, M. avium, M. ulcerans and M. marinum. 
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Figure 1.19 An iTOL-generated taxonomy based phylogenetic tree.  The tree shows the 
number of mycofactocin encoding species identified in each genus. The indicated genera are color 
coordinated by phylum where pink represents Actinobacteria, green represents Chloroflexi, 
magenta represents Firmicutes, cyan represents Proteobacteria and purple represents 
Euryarchaeota.       
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1.7.3 Biosynthesis of Mycofactocin 
           Six strictly conserved genes, mftABCDEF were identified to be responsible 
for the biosynthesis of mycofactocin (169). The genes mftA, mftB and mftC encode 
the precursor peptide MftA, the peptide chaperone MftB and the radical SAM 
enzyme MftC respectively while the remaining genes mftD, mftE and mftF encode 
the flavin dehydrogenase MftD, the creatinase homolog MftE, and the 
glycosyltransferase MftF. Sequence homology alignment of MftA sequence from 
250 different species revealed strict conservation of the C-terminal residues. The 
C terminal -SIDGMCGVY sequence was found to be strictly conserved among all 
250 different species (Figure 1.20) (98, 169).  The strict conservation of the C-
terminal sequence led Haft to suggest that mycofactocin biosynthesis parallels that 
of PQQ. As described above, PQQ is a redox cofactor derived from extensive 
chemical modification of the evolutionarily conserved tyrosine and glutamate 
residues on the precursor peptide PqqA (see Figure 1.16 for details).  
 
 
Figure 1.20 The mycofactocin precursor peptide and gene context. The amino acid sequence 
alignment of the MftA from 250 different species created by WebLogo. Highlighted in the blue box 
are the most conserved C-terminal resides of MftA. 
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           In addition, the gene product, MftB was found to share high structural 
homology with the RRE domain PqqD, involved in the biosynthesis of PQQ (see 
Figure 1.7).  Furthermore, sequence homology alignment of the radical SAM 
enzyme MftC revealed the similarity of its C-terminal extension to that of RS-
SPASM enzymes known to catalyze carbon-carbon bonds and carbon-sulfur 
bonds (82). Taken together, the bioinformatic data indeed suggests that 
mycofactocin a RiPP derived product and its biosynthesis and function parallels to 
that of PQQ (169). To determine the structure of mycofactocin and thereby gain 
insight into its physiological role, recent efforts have aimed at in vitro reconstitution 
of each enzyme in the pathway, to understand their role and function in the 
biosynthesis of mycofactocin. 
          The biosynthesis of mycofactocin commences with the ribosomal production 
of the precursor peptide, MftA containing the strictly conserved C-terminal 
SIDGMCGVY motif. The first chemical transformation in the biosynthesis involves 
the RS enzyme MftC, and the RRE domain MftB in the presence of SAM. For this 
to occur, the RRE domain protein MftB, must engage both the radical SAM enzyme 
MftC and MftA to form a ternary complex, thereby bringing both MftA and MftC into 
catalytically relevant proximity and orientation for chemical transformations to 
occur. In the presence of SAM and a one-electron reductant such sodium dithionite 
(DTH), an electron is transferred from the RS-cluster into SAM resulting in the 
homolytic cleavage of SAM to form 5’-deoxyadenosine radical. This radical 
subsequently abstracts a hydrogen atom from the Cβ position of the C-terminal 
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tyrosine to form a substrate radical. Delocalization of the radical into the phenyl 
ring followed by an oxidative decarboxylation of the tyrosine results in the formation 
of an α/β unsaturated product, MftA** (Figure 1.21A). Intriguingly, two independent 
studies, one from our lab demonstrated that MftC indeed, catalyzes the oxidative 
decarboxylation of the C-terminal tyrosine to form MftA** (74, 98). A subsequent 
study demonstrated that MftE, a member of the creatinine amidohydrolase family, 
was the likely candidate for being the next processing enzyme in the pathway. This 
was based on a biochemical study that concluded that MftE hydrolyzes the last 
two residues from MftA**, resulting in the formation of Val-p-(2-aminoethenyl) 
phenol moiety (185). However, in a follow-up study from our lab on the catalytic 
mechanism of MftC, it was shown that MftA** is an intermediate of a two-step 
reaction. In the second step, another molecule of SAM is used to generate a 
5’deoxyadenosine radical which abstracts a hydrogen atom from the side chain of 
Val29 to form an alkyl radical. This newly formed radical subsequently attacks the 
adjacent α/β unsaturated bond of tyrosine to form a carbon-carbon crosslink and 
a radical at Cα position of tyrosine. This radical is then quenched by injecting an 
electron and a proton into the reaction to form a biologically relevant crosslinked 
product MftA* (99) (Figure 1.21B).  
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Figure 1.21 Proposed mechanism for MftC catalysis. The reaction mechanism of MftC catalysis 
showing the consumption of two equivalence of SAM to form the final product MftA*. (A) Oxidative 
decarboxylation reaction to form MftA** and (B) Redox neutral C-C crosslink reaction to form MftA*. 
 
 
 
 
1.7.4 Objectives and scope of this dissertation 
           Because multiple products are produced by MftC and guiding experimental 
data regarding the structure of mycofactocin are lacking, a new question about the 
identity of the precursor for mycofactocin, MftA* or MftA**, has arisen. That is, 
which of the two products is recognized by MftE and carried forward in the 
biosynthesis of mycofactocin (Figure 1.22). In addition, the role of the remaining 
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gene products MftD and MftF, in the biosynthesis of mycofactocin is unknown. 
Lastly, the notion that MftC catalyzes two distinct chemistries in the same active 
site, an oxidative decarboxylation of the C- terminus (Figure 1.21A) and a 
subsequent redox neutral C−C crosslink (Figure 1.21B) is interesting. This is 
because the reactions catalyzed by members of radical SAM protein family can be 
described as either oxidative or redox neutral, but MftC seems to be an outlier in 
that it can “redox-flip”. The ability of MftC to redox-flip, or accommodate both 
oxidative and redox neutral reactions in the same active site, is certainly unique to 
the RS-SPASM subfamily, in which all proteins characterized to date have been 
shown to catalyze net oxidative reactions on their peptide substrate (186).   
           The work presented in this dissertation focuses on addressing the concerns 
described above. This includes (i) investigation of the structural effect of MftC on 
its catalysis and how it’s able to redox-flip (ii) investigation of which product of MftC 
catalysis is carried forward in the biosynthesis of mycofactocin, (iii) investigation of 
the role of MftD in the biosynthesis of mycofactocin and the physiological role of 
the product of the pathway (Figure 1.22). 
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Figure 1.22 Steps in the biosynthesis of mycofactocin highlighting the focus of this 
dissertation.  (i) MftC catalyzes the oxidative and redox neutral reactions in the same active site 
to form two products MftA* and MftA**. (ii) Which of the products of MftC is carried forward in the 
biosynthesis of mycofactocin? That is, does MftE recognize MftA* or MftA** and (iii) what kind of 
chemical modification does MftD impart on the product of MftE hydrolysis and what is the 
physiological role of mycofactocin. 
 
           I began by employing biochemical, spectroscopic and electrochemical 
techniques to investigate the roles of the auxiliary clusters in MftC catalysis. This 
was done using mutagenesis and activity assays to investigate the role of the 
auxiliary clusters in MftC. The number and type of auxiliary clusters in MftC were 
subsequently analyzed by Mossbauer spectroscopic techniques. This was a 
collaborative work with the Pandelia lab at Brandeis University. Furthermore, the 
redox potentials of all three clusters in MftC were measured using electrochemical 
techniques to gain insights into the redox flipping mechanism of MftC. This work 
was done in conjunction with the Elliot lab at Boston University.  
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           Having investigated the role of the auxiliary clusters in MftC, the activity of 
MftE was revisited to clarify which product of MftC is carried forward in the 
biosynthesis of mycofactocin. To do this, activity assays were combined with high 
pressure liquid chromatography HPLC techniques to analyze MftE reactions with 
MftA, MftA* and MftA**. The structure of the product was solved by combining high 
resolution mass spectroscopy (HRMS) with NMR spectral workup. The effect of 
metals and other parameters on the rate of hydrolysis of MftE were also 
investigated. The results obtained from this study provided insights into the 
biologically relevant precursor for mycofactocin biosynthesis. 
           Having determined which product of MftC is the precursor for mycofactocin 
biosynthesis, the activity of the next processing enzyme, MftD was investigated. 
This was done by combining activity assays and biochemical techniques to 
demonstrate that MftD is active towards the product of MftE hydrolysis reaction. 
The type of modification that was imparted on the product of MftE hydrolysis by 
MftD was also investigated. This was done by combining HPLC and LCMS 
techniques with NMR spectral work up to solve structure of the reaction product. 
The midpoint potential for the new molecule was subsequently measured using 
cyclic voltammetry. Lastly, the physiological function of mycofactocin was probed 
by coupling it to the enzymatic activities of mycofactocin-associated short chain 
dehydrogenases. The experimental data presented in this dissertation have 
coalesced to provide the first direct evidence for the physiological role of 
mycofactocin. 
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CHAPTER TWO: METHODS 
2.1 General Methods 
2.1.1 High Resolution Mass Spectrometry (HRMS) 
           All samples for HRMS were analyzed by nano-flow LC-ESI-MS (Thermo 
Scientific LTQ Orbitrap Velos Pro) at the Biological Mass Spectrometry facility, 
University of Colorado Anschutz Medical Campus. Prior to analysis, samples were 
desalted using a C18 ZipTip (EMD Millipore). Data were analyzed using XCalibur 
Qual Browser v. 3.0.63 (Thermo Scientific). 
 
2.1.2 Nuclear Magnetic Resonance (NMR) Assay 
           All NMR Spectra were recorded on Bruker UltraShield 500/54 Plus 
Spectrometer. Spectra were processed in Topspin v. 2.1 program (Bruker) using 
deuterated water as solvent. Water suppression signal was applied at a frequency 
of 2353.37 Hz. All NMR spectra were analyzed using MestReNova v. 12.0.0-20080 
program (Mestrelab Research). 
 
2.1.3 HPLC program 
           All reactions were filtered through 0.2 μm spin columns to remove all 
precipitated proteins. The supernatants were pipetted into 300 μL autosampler 
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HPLC vials and injected directly into a reverse-phase Jupiter C5, 5 μm, 4.6 × 250 
mm column (Phenomenex) using Shimadzu Prominence-i LC-2030C HPLC and 5 
mM sodium phosphate, pH 7.5 (buffer A) and 5 mM sodium phosphate in 70% 
acetonitrile pH 7.5 (buffer B). A linear gradient of solvent B from 0% to 35% was 
applied from 2 to 8 min, which was followed by a linear gradient to 100% solvent 
B from 8 to 17 min. Solvent B was then held constant at 100% from 17 to 19 min 
followed by linear decrease to 100% solvent A from 19 to 22 min. Solvent A was 
held constant for an additional 2 min to re-equilibrate the column before 
subsequent sample injections. Chromatograms were reported at 280 nm while 
monitoring wavelengths between 200 and 400 nm. New peaks were isolated, 
lyophilized, and analyzed by NMR and HRMS 
 
2.1.4 Analytical size exclusion chromatography 
           Analytical size exclusion chromatography was run on purified wildtype and 
variants of MftC, MftE and MftD proteins by injecting 100 µl of the protein (200 µM) 
onto a Superdex 200 10/300 GL column (GE Life Sciences) at a flow rate of 0.8 
mL/min and using the protein storage buffer as the mobile phase. Biorad Gel 
Filtration Standards containing protein standards for 670 kDa (thyroglobulin), 158 
kDa (γ-globulin), 44 kDa (ovalbumin), 17 kDa (myoglobin) and 1.35 kDa (vitamin 
B-12) were used to prepare a standard curve. 
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2.2 Expression and purification of MftA from Mycobacterium ulcerans 
Agy99 
           The unannotated gene sequence of MftA from Mycobacterium ulcerans 
Agy99 was cloned into pET28HST vector using NdeI and XhoI restriction sites. 
The plasmid was designed to add a His6-SUMO tag to the N-terminus of the 
protein. The sequence verified mftA/pET28HST plasmid was transformed into 
BL21 Star (DE3) (Invitrogen) competent cell line and grown overnight. The 
overnight culture was used to inoculate 4 L of LB medium. The cells were grown 
at 37°C with shaking at 200 rpm until OD600 ~ 0.6 was reached, at which point 
protein production was induced by the addition of 1 mM IPTG (isopropyl-β-
thiogalactopyranoside) and grown at 21°C overnight with shaking at 200 rpm. The 
cell culture was centrifuged at 7000 rpm for 10 min, and the resulting cell pellet 
was suspended in 5-fold cell weight lysis buffer (50 mM Tris, 200 mM NaCl, 25 
mM Imidazole, pH 7.6). To the suspension was added 0.1 mg/g of lysozyme, 0.1 
mg/g of DNase and 1% w/v CHAPS and stirred for an additional 30 mins. Lysis 
was completed by sonicating the suspension for 5 mins and centrifuging at 13000 
rpm for 15 min. The supernatant was loaded onto a 5 mL HisTrap column (GE Life 
Sciences) using an ÄKTA FPLC system. The column was washed with 5 column 
volumes of lysis buffer (50 mM Tris, 200 mM NaCl, 25 mM Imidazole, pH 7.6). 
Bound proteins were eluted using elution buffer containing 50 mM Tris, 200 mM 
NaCl, 300 mM Imidazole, pH 7.6. The purified SUMO-MftA protein fraction was 
collected and buffer exchanged into the sodium phosphate buffer (5 mM 
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Na2HPO4, 1 mM TCEP, pH 7.5) using HiPrep 26/10 Desalting column (GE Life 
Sciences) and concentrated using 10 kDa spin columns (Amicon ultra). Tobacco 
etch virus (TEV) protease was added and incubated at 4°C overnight. The resulting 
protein/protease mixture was centrifuged at 14000 rpm for 5 min and the 
supernatant was analyzed by reverse phase HPLC using the program described 
above.  
 
2.3 Expression and purification of MftB from Mycobacterium ulcerans 
Agy99 
           The Mul_0772 gene sequence encoding for MftB from Mycobacterium 
ulcerans Agy99 (Uniprot: A0PM48) was cloned into pGEX6p-1 vector using BamHI 
and XhoI restriction sites to obtain the GST-MftB fused protein. The sequence 
verified MumftB/pGEX6p1 plasmid was transformed into E. coli T7Iq Express 
(NEB) and grown overnight at 37 oC and 200 rpm. The overnight culture was used 
to inoculate 4 L of LB medium containing 100 µg/mL of Ampicillin and 34 µg/ml of 
chloramphenicol. The culture was grown at 37 oC and 200 rpm. When an OD600 ~ 
0.6 was attained, protein production was induced by addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration of 1 mM and allowed to grow 
at 21 oC overnight with shaking at 200 rpm. Cells were harvested and suspended 
in five times the mass of pellets of lysis buffer containing 50 mM HEPES (pH 7.5), 
300 mM NaCl and 1 mM tris(2-carboxyethyl) phosphine (TCEP). To this 
suspension was added 0.1 mg/g of lysozyme, 0.1 mg/g of DNase and 1 % w/v 
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CHAPS and stirred for 30 min. Lysis was completed by sonication for 5 min and 
the lysate was clarified by centrifugation at 13000 rpm for 10 min. The supernatant 
was introduced into Coy Lab anaerobic chamber maintained under an atmosphere 
of 90% nitrogen and 10% hydrogen gases (oxygen concentration maintained 
below 20 ppm by palladium catalysts). The supernatant was loaded onto a 5ml 
GSTrap FF column (GE Healthcare) pre-equilibrated with lysis buffer using an 
AKTA Start FPLC (GE Healthcare). The loaded column was washed with five 
column volumes of lysis buffer and bound protein was eluted using 50 mM HEPES 
buffer (pH 7.5) containing 300 mM NaCl, 30 mM Glutathione HCl and 1 mM TCEP. 
Fractions containing proteins were pooled together and buffer exchanged into 50 
Mm HEPES storage buffer (pH 7.5) containing 300 mM NaCl, 10% glycerol and 1 
mM TCEP using PD-10 columns (GE Healthcare). The protein was concentrated 
using 10 kDa spin concentrators (Millipore Amicon Ultra), aliquoted into 1.5 mL 
HPLC vials, flash-frozen and stored at -80 °C until use. 
 
 
2.4 Generation of RS, Aux I, and Aux II KO Variants of MftC.  
           To produce MftC knockout variants, cysteine residues identified in the 
bioinformatic study described above were replaced with alanine to generate the 
radical SAM cluster knockout (RS KO), the auxiliary I cluster knockout (Aux I KO), 
and the auxiliary II cluster knockout (Aux II KO) variants of MftC. Site-directed 
mutagenesis and sequence verification were performed by Genscript. For the RS 
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KO variant, the C30A/C37A double mutant was used. For the Aux I KO variant, the 
single C323A mutant was used. For the Aux II KO variant, the C310A/C341A 
double mutant was used. 
 
2.5 Expression and purification of MftC from Mycobacterium ulcerans 
Agy99 
           The Mul_0773 gene sequence encoding for MftC from Mycobacterium 
ulcerans Agy99 (Uniprot: A0PM49) was cloned into pET28a vector using NdeI and 
XhoI restriction sites. The sequence verified MumftC/pET28a plasmid was 
transformed into E. coli BL21 (DE3) competent cells containing the iron-sulfur 
cluster builder plasmid pPH149 for protein expression. An overnight culture of E. 
coli BL21 (DE3)- MumftC/pET28a/pPH149 was grown in 10 mL of LB medium 
containing 50 µg/mL of kanamycin and 34 µg/mL chloramphenicol at 37 oC 
overnight at 200 rpm. The overnight culture was used to inoculate 4 L of terrific 
broth (TB) growth medium and incubated at 37 oC with shaking at 200 rpm until an 
OD600 of ~1.0 was attained. Protein production was induced by the addition of 
IPTG to a final concentration of 1 mM, 0.75g/L of sodium fumarate and 1 mL/L of 
1000 x trace metals. Following a 20 h induction period at 21 oC and 200 rpm, cells 
were harvested by centrifugation at 7000 rpm for 10 min and stored at -80 oC until 
lysis. All purification steps were carried out in the anaerobic chamber. The thawed 
cells were introduced into the anerobic chamber and resuspended in five times the 
mass of cell pellet of lysis buffer (pH 8.0) containing 50 mM HEPES, 300 mM KCl 
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and 50 mM imidazole. To this suspension was added 0.1 mg/g of lysozyme, 0.1 
mg/g of DNase and 1 % w/v CHAPS and stirred for 30 min at room temperature to 
complete the lysis process. The resulting lysate was clarified by centrifugation at 
13000 rpm for 10 min at 4 oC. The supernatant was loaded onto a 5 ml HisTrap FF 
column (GE Healthcare) pre-equilibrated with lysis buffer using an AKTA Start 
FPLC. The loaded column was washed with five column volumes of lysis buffer 
and the bound protein was eluted using 50 mM HEPES buffer (pH 8.0) containing 
300 mM KCl, 300 mM imidazole. Fractions containing MftC proteins were pooled 
together and buffer exchange in storage buffer (pH 8.0) containing 50 mM HEPES, 
300 mM KCl, 10 mM DTT and 10% glycerol over PD-10 columns (GE Healthcare). 
MuMftC cluster knockout strains were expressed and purified in the same manner 
as described above. The resulting volume of MftC protein was reconstituted as 
described below. 
 
2.6 Reconstitution of MftC 
           Purified MftC protein was reconstituted anaerobically as previously 
described (98, 99). In summary, to a 15 mL solution of 150 µM MftC in storage 
buffer (pH 8.0) containing 50 mM HEPES, 300 mM KCl, 10% glycerol and 10 mM 
DTT, was added 1.8 mM FeCl3 and 1.8 mM Na2S and stirred for 30 min on ice. 
The reconstituted protein was centrifuged at 5000 rpm for 5 min to remove 
precipitates. The supernatant containing soluble MftC protein was buffer 
exchanged into fresh storage buffer (pH 8.0) containing 50 mM HEPES, 300 mM 
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KCl, 10% glycerol and 10 mM DTT using a PD-10 column (GE Healthcare). The 
resulting volume of reconstituted protein was concentrated using 30 kDa spin 
columns (Millipore Amicon Ultra), aliquoted into 1.5 mL airtight HPLC vials, flash-
frozen and stored at -80 oC until use. 
 
2. 7 Bioinformatic Analysis of MftC 
           To bioinformatically analyze the gene context and distribution of MftC, the 
amino acid sequence for M. ulcerans Agy99 MftC (Uniprot: A0PM49) was used in 
a BLAST search of the Uniprot database. The BLAST search used in default 
settings except that the E-threshold was set to 0.001 and the number of hits was 
set to 1000. Approximately 760 hits with a sequence identity of >35% were carried 
forward for the remaining analysis. Proteins with ≥85% sequence identity (∼310) 
were classified as MftC by default. The genomes of the organisms that contained 
homologous proteins with sequence identities between 85 and 35% were 
examined to verify that the putative homologues were indeed MftC. The curated 
genomes of the organisms found on the EnsemblBacteria database or the NCBI 
Gene database were searched for the precursor peptide MftA. The homologues of 
the genomes containing an annotated MftA with the conserved sequence − 
SIDGMCGVY were confirmed as MftC (169). Those genomes that did not have an 
annotated MftA were further examined to identify at least two other genes 
associated with mycofactocin biosynthetic cluster, such as mftB, mftD, mftE, or 
mftF (182). If the genome containing the MftC homologue contained two of the 
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aforementioned genes within a 10 kb window, the homologue was validated as 
MftC. If a curated genome in the two databases was unavailable for the organism 
that contained the putative homologue, the homologue was classified as annotated 
and carried forward in the analysis as if it were MftC. Of the remaining ∼720 
homologues, species duplicates were removed, leaving 625 unique species 
containing a putative MftC. To identify which cysteines on MftC are strictly 
conserved, a sequence alignment of all 625 unique MftC amino acid sequences 
was carried out using the Constraint-based Multiple Alignment Tool (COBALT) 
provided on the NCBI Web site 
(ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi?CMD=Web). The sequence alignment file 
was downloaded and used as the input in the server program, Weblogo (187) for 
visualization. MftC protein structure models were generated by the server program, 
Phyre2.0.1. Using the expert mode program, one-to-one threading, the amino acid 
sequence for M. ulcerans MftC was input along with the Protein Databank identifier 
for anSME (PDB ID: 4K36) (117), CteB (PDB ID: 5WHY) (83) or SuiB (PDB ID: 
5V1T) (110). The threaded MftC structural models were overlaid with their 
respective parent structure using Chimera’s Match Maker tool to visualize the 
conserved cysteines of MftC and their vicinity to the parent structure’s [Fe−S] 
clusters. 
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2.8 Iron and sulfur quantification 
           Protein concentrations were estimated using a Bradford assay. To 
determine the iron concentration of reconstituted MftC, 100 μL of 20 μM protein 
was mixed with 10 μL of 3 M trichloroacetic acid. The precipitated protein was 
centrifuged at 15,000g for 10 min. The supernatant was carefully removed and 
diluted with 330 μL of diH2O. To the solution, 20 μL of sodium ascorbate, 20 μL of 
10 mM ferrozine, and 20 μL of saturated sodium acetate were added. The 
absorbance change due to the ferrozine−iron complex was measured at 562 nm 
(ε = 27.9 mM−1 cm−1). To determine the sulfur concentration, 200 μL of 10 μM 
protein was mixed with 600 μL of 1% (w/v) zinc acetate and 50 μL of 7% (w/v) 
sodium hydroxide. The solution was incubated at room temperature for 15 min 
after which 150 μL of 0.1% (w/v) N, N-dimethyl-p-phenylenediamine (in 5 M HCl) 
and 150 μL of 10 mM FeCl3 (in 1 M HCl) were added. The solution was vortexed 
and incubated at room temperature for 20 min. The absorbance from methylene 
blue was measured at 670 nm (ε = 34.5 mM−1 cm−1). For both assays, blanks were 
generated by substituting protein with deionized water. 
 
2.9 MftC activity assays  
           All reactions were conducted in a Coy anaerobic chamber maintained under 
an atmosphere of 97% nitrogen and 3% hydrogen gases. MftC variants were 
assayed for uncoupled cleavage of SAM and complete modification of MftA 
following previously described procedures (99). For SAM cleavage assays, a 
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reaction containing 2 mM SAM, 10 mM DTT, 2 mM dithionite, and 100 μM of 
wildtype MftC or variant in 50 mM HEPES, 200 mM NaCl was incubated in an 
anaerobic chamber overnight. The reactions were analyzed by HPLC over a 
Phenomenex Jupiter C4 5 μm 300 Å reverse phase column using 0.1% TFA and 
acetonitrile as solvents. For peptide modification assays, the same reaction was 
set up with the addition of 100 μM MftA and 100 μM MftB. The reactions were 
analyzed on reverse phase HPLC as described above. 
 
2.10 Preparation of MftC for Mossbauer Spectroscopy 
             57Fe2O3 (Cambridge Isotope Laboratories) was converted to 57FeCl3 by 
incubating the oxide in 1 M HCl at 80 °C overnight. An overnight starter culture 
containing E. coli Bl21 (DE3) transformed with pPH151 and mftC/pET28a was 
used to inoculate 8 L of M9 minimal media (Sigma-Aldrich) supplemented with 20 
amino acids (0.2 g/L) and 1X auto induction metals, excluding iron. The large-scale 
culture was incubated at 37 °C with shaking until OD600 ∼ 1.2 was reached. At 
this point, 1 mM IPTG, 0.75 g/L sodium fumarate, and 57Fe (75 μM) were added to 
the cultures and the flasks were sealed. The induced cultures were incubated at 
20 °C overnight, and the cells were harvested by centrifugation. The cell pellet was 
introduced into the anaerobic chamber and suspended in anaerobic lysis buffer, 
and MftC was purified as described above. Reconstitution of MftC was carried out 
as described above except that 57FeCl3 was substituted for FeCl3 and the 
reconstituted protein was buffer exchanged over a PD-10 column twice. Iron and 
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sulfur quantification were performed for all protein samples prior to being 
characterized by Mossbauer spectroscopy. All Mossbauer spectroscopic 
experiments were performed by the Pandelia lab at Brandeis University.  
 
2.11 Electrochemical Measurements of MftC  
           Electrochemical experiments on MftC were performed by the Elliott Lab at 
Boston University using the following procedures. They performed all experiments 
anaerobically in a MBraun Labmaster glovebox using a PGSTAT12 potentiostat. 
A three-electrode configuration was used in a water-jacketed glass cell. A platinum 
wire was used as the counter electrode, and a standard calomel electrode was 
used as the reference electrode. Reported potentials are relative to the standard 
hydrogen electrode. Baseline measurements were collected using an edge-plane 
graphite (EPG) electrode pretreated by mechanical polishing with sandpaper 
followed by incubating overnight with 14 μL of 3 mg of multiwalled carbon 
nanotubes (MWCNT) (Sigma, 10 ± 1 nm × 4.5 ± 0.5 nm × 3.6 μm) dissolved in 1 
mL of dimethylformamide (DMF) by sonication for 15 min. The electrode was then 
rinsed and placed into a glass cell containing a mixed buffer solution (10 mM 
HEPES/CHES/ MES/TAPS/CAPS, 200 mM NaCl) and pH 7.5. A 4 μL aliquot of 
either wild-type MftC, the RS KO, or the Aux II KO variant was applied directly to 
the electrode surface and allowed to sit for approximately 2 min at room 
temperature before being placed into the buffer cell solution. Cyclic 
voltammograms were collected at 4 °C with a scan rate of 50 mV/s and 
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electrochemical signals were analyzed using QSoas (188), where the data are 
presumed to represent all three iron−sulfur clusters of MftC. Voltammograms were 
fit to three Nernstian components as described where the surface coverage for all 
components is the same, and napp and the redox potentials are fit as floatable 
parameters (189). Square wave measurements were collected at 4 °C with a 
frequency of 10 Hz and an amplitude of 20 mV. 
 
2.12 Production of MftA* and MftA** 
           All reactions were conducted in a Coy anaerobic chamber maintained under 
an atmosphere of 97% nitrogen and 3% hydrogen gases. The oxygen 
concentration was maintained below 20 ppm by palladium catalysts. MftC 
reactions were conducted in a total volume of 500 µL and contained 50 mM 
HEPES reaction buffer (pH 8.0), 300 mM KCl, 10 mM dithiothreitol (DTT), 10% 
glycerol. The order of addition of reagents is as follows: 300 µM of substrate MftA 
and 300 µM of GST-MftB were added sequentially followed by 5 min of incubation 
period. To the reaction was added 300 µM MftC, 2 mM S-adenosylmethionine 
(SAM) and 2 mM sodium dithionite (DTH) consecutively and the resulting mixture 
was incubated at room temperature overnight. The reaction was then filtered with 
10 kDa cut off 500 µL spin columns to remove all precipitated proteins. The filtrate 
was pipetted into 1.5 mL HPLC autosampler vials and MftA* was separated by 
reverse-phase chromatography on a Shimadzu Prominence-i-LC-2030C HPLC as 
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described above. MftA* and MftA** peaks were collected, lyophilized and analyzed 
by NMR or used for subsequent reactions. 
 
2.13 Generation of a sequence similarity network for the creatinine 
amidohydrolase family.  
           A sequence similarity network (SSN) of the creatinine amidohydrolase 
family was generated using the Enzyme Function Initiative Enzyme Similarity Tool 
(ESI-EST) (190). The Interpro identifier IPR003785 was used in Option B method 
and sequences were restricted to those of UniRef 90 seed sequences. The 
network was constrained using an E-value of 10-35, sequence lengths between 
220-280 and sequence identities of 50%. The resulting network, containing 2,344 
nodes, was colored using the Color SSN tool on the EFI-EST website. The network 
was visualized in Cytoscape3.7.2 and the mycofactocin cluster was re-colored to 
green. 
 
2.14 Expression and purification of MftE from Mycobacterium 
ulcerans Agy99 
           The amino acid sequence of MftE (Uniprot: A0PM51) from Mycobacterium 
ulcerans Agy99 was used for E. coli optimized gene synthesis (Genscript). The 
resulting mftE gene was cloned into pGEX6p1 using the BamHI and XhoI 
restriction sites. The sequence verified MumftE/pGEX6p1 plasmid was 
transformed into chemically competent E. coli BL21 star (DE3). An overnight 
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culture of E. coli BL21 star (DE3)-MumftE/pGEX6p1 was grown in 10 mL of LB 
medium containing 100 µg/mL of Ampicillin at 37 oC and 200 rpm was used to 
inoculate 4 L of the same medium. The culture was incubated at 37 oC with shaking 
at 200 rpm until an OD600 ~ 0.8 was reached. Protein production was induced by 
the addition of ITPG to a final concentration of 1 mM, and the cells were incubated 
for an additional 24 h at 20 oC with shaking at 200 rpm. The cells were harvested 
and resuspended in lysis buffer (pH 7.7) containing 50 mM HEPES and 200 mM 
NaCl. To the suspension was added 0.1 mg/g of lysozyme, 0.1 mg/g of DNase and 
1 % w/v CHAPS and stirred on ice for an additional 30 min. The cells were 
disrupted by sonication for 4 min and the resulting lysate was centrifuged at 13000 
rpm for 10 min. The supernatant was loaded onto a 5 mL GSTrap FF column 
equilibrated with lysis buffer using an AKTA Pure FPLC. The column was washed 
with five column volumes of lysis buffer and the bound protein was eluted with 50 
mM HEPES buffer (pH 7.7) containing 200 mM NaCl and 30 mM reduced 
glutathione. Fractions containing MftE proteins were pooled together and buffer 
exchanged into storage buffer (pH 7.7) containing 50 mM HEPES, 200 mM NaCl, 
1 mM TCEP and 1% glycerol, using a HiPrep 26/10 desalting column. The protein 
was concentrated using a 30 kDa spin concentrators, aliquoted into 1.5 mL HPLC 
vials, flash-frozen and stored at -80 oC until use. 
 
 68 
 
2.15 Expression and purification of MftE from Mycobacterium 
smegmatis mc2 155 
           The Ms_1425 gene sequence for MsMftE (Uniprot: A0QSC0) was amplified 
from the genomic DNA isolated from Mycobacterium smegmatis mc2 155 and 
cloned into pGEX6P-1 (GE Life Sciences) using the BamHI and XhoI restriction 
sites. The MsMftE protein was expressed and purified in a method similar to that 
described for MuMftE above. 
 
2.16 Analysis of metal ion content in MftE  
           The types and amounts of metal ions present in MftE was determined by 
ICP-MS in the Majestic Lab at the Department of Chemistry and Biochemistry, 
University of Denver. Prior to the analysis, a fraction of the as-purified MftE was 
reconstituted on ice with two eq of Fe (NH4)2(SO4)2 and/or ZnCl2. The reconstituted 
protein was buffer exchanged into storage buffer (50 mM HEPES, 200 mM NaCl, 
1 mM TCEP and 1% glycerol, pH 7.7) using PD-10 columns (GE Life Sciences) 
and concentrated using 10 kDa spin (Millipore Amicon Ultra). The Zn2+ and/or Fe2+ 
reconstituted MftE was used for protein concentration estimation by Bradford 
assay and for metal quantification by ICP-MS. 
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2.17 Substrate Screening for MftE and production of 3-amino-5-[(p-
hydroxyphenyl) methyl]-4,4-dimethyl-2-pyrroli-dinone (AHDP). 
           MftE modification reactions were set up as follows: 50 µM of MftE was 
added to a reaction buffer containing 50 mM HEPES, 300 mM NaCl, 1% glycerol, 
1 mM TCEP, pH 7.7. For substrate specificity screening, 50 µM (1 eq) of ferrous 
ammonium sulfate and zinc chloride were added and incubated-on ice for 5 mins. 
Modified and unmodified MftA (50 µM MftA, 50 µM of MftA* and or 50 µM MftA**) 
were added to the reaction mixture where appropriate. Control reactions were set 
up in similar fashion except buffer was substituted for individual reagents or 
proteins. Reactions were incubated at room temperature for 3 hr after which they 
were filtered through a 0.2 µm spin columns to remove all precipitated proteins. 
The supernatant was either flash frozen and stored at -80 oC until ready to be 
analyzed or injected directly onto a reverse-phase HPLC system and separated 
according to the above HPLC described program. New peaks were isolated and 
analyzed by NMR and LC/MS. Activity assays for MftE from M. smegmatis were 
set up in the manner described for MuMftE.  
 
2.18 Labeling of MftA  
           The generation of the 13C, 15N labelled MftA followed previously reported 
procedures, with some modifications (99). In short, M1W mftA/pET28HST plasmid 
was transformed into E. coli BL21 Star (DE3) (Invitrogen). An overnight culture 
was used to inoculate 4 L of M9 minimal media containing 4 mL/L glycerol, 25 mM 
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Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 1 mM MgSO4, 100 µM 
CaCl2, 50 µM trace metals, 50 mg/L each of the 18 unlabeled amino acids and 50 
mg/L of 13C and 15N-labeled tyrosine and valine (Cambridge isotope laboratory) 
pH 6.8. The cells were grown at 37 oC A600 ~ 0.6. His6-SUMO-MftA production was 
induced with 1 mM IPTG and the temperature was reduced to 21 oC. After ~12 hr, 
cells were harvested by centrifugation at 7000 rpm for 10 mins at 4 oC and the 
resulting pellet was suspended in lysis buffer (50 mM HEPES, 200 mM NaCl, 25 
mM imidazole pH 7.6). CHAPS (1%), lysozyme (1mg/g of cell paste) and DNase 
(0.5mg/g of cell paste) were added and stirred on ice for 20 mins. Cell lysis was 
completed by sonication and the lysate was centrifuged at 13000 rpm for 10 mins 
at 4 oC. The supernatant was loaded onto a 5 mL HisTrap column using an AKTA 
Pure FPLC (GE Healthcare) system. The column was washed with lysis buffer 
followed by elution buffer (50 mM HEPES, 200 mM NaCl, 300 mM Imidazole, pH 
7.6). The fractions containing the His6-SUMO-MftA were pooled together and 
buffer exchanged into storage buffer (50 mM Hepes, 200 mM NaCl, 1 mM TCEP, 
pH 7.6) using a HiPrep 26/10 Desalting column (GE Life Sciences). The protein 
was concentrated using a 10 kDa spin columns (Millipore Amicon Ultra). Tobacco 
etch virus (TEV) protease was added to the protein and incubated at 4 oC 
overnight. The MftA/SUMO/TEV protease mixture was separated on reverse-
phase HPLC using the program described above. Peaks corresponding to the 
heavy labeled peptide were collected, lyophilized and used for further analysis. 
 
 71 
 
2.19 Kinetic Analysis of MftE 
           Kinetic analysis of MftE was carried out under single turnover conditions 
(Figure SI4). A 500 µL reaction was setup to contain 60 µM MftE reconstituted with 
Zn2+ and/or Fe2+, in the reaction buffer described above, and 50 µM of MftA*. At 
interval times, 50 µL aliquots were extracted, filtered through a 0.2 µm spin 
columns and either flash frozen or immediately used directly in HPLC analysis. 
Frozen samples were rapidly thawed and immediately used in HPLC analysis. 
HPLC analysis of the reactions were carried out as described above. The MftA* 
peaks were integrated and plotted versus time. Rates of the single turnover 
reaction were extracted from single exponential decay fits (GraphPad Prism 7.0). 
 
 
2.20 Generation of sequence similarity network for alpha-hydroxy acid 
oxidase family.  
           A sequence similarity network (SSN) of the alpha-hydroxy acid oxidase 
family was generated using the Enzyme Function Initiative Enzyme Similarity Tool 
(ESI-EST) (190). The Interpro identifier IPR012133 was used in Option B method 
and sequences were restricted to those of UniRef 90 seed sequences. The 
network was constrained using an E-value of 40, sequence lengths between 320-
450 and sequence identities of 50%. The resulting network, containing 2,215 
nodes, was colored using the Color SSN tool on the EFI-EST website. The network 
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was visualized in Cytoscape4 and the mycofactocin system oxidoreductase MftD 
was colored to yellow. 
 
 
2.21 Cloning, Expression and Purification of MftD from M. ulcerans 
Agy99 
           The mul_0774 gene sequence encoding for MftD from Mycobacterium 
ulcerans Agy99 (Uniprot: 0PM50) was cloned into pET28a-TEV using BamHI and 
XhoI restriction sites. The sequence verified MumftD/pET28a-TEV plasmid was 
transformed into E. coli ArcticExpress (DE3) (Stratagene) for protein production. A 
50 mL overnight culture of the E. coli ArcticExpress (DE3)-MumftD/pET28a-TEV 
was used to inoculate 4 L of the same medium containing 50 μg/mL of kanamycin 
and 10 μg/mL of tetracycline and supplemented with 100 μM riboflavin. The culture 
was incubated at 37 °C with shaking at 200 rpm until an OD600 ≈ 0.6 was attained, 
at which point MftD production was induced by addition of IPTG to a final 
concentration of 1 mM. Following a 24 h induction at 13 °C with shaking at 200 
rpm, the cells were harvested by centrifugation at 7000 rpm for 10 min and stored 
at −80 °C until lysis. All purification steps were carried out in a Coy Lab anaerobic 
chamber maintained under an atmosphere of 97% N2 and 3% H2 gases. The 
harvested cells were thawed and resuspended in 5 times pellet mass of lysis buffer 
containing 2X phosphate-buffered saline (PBS) buffer (pH 8.0), 30 mM imidazole 
and 2 mM dithionite (DTH). To the suspension was added 0.1 mg/g of lysozyme, 
0.1 mg/g of DNase and 1% w/v CHAPS and stirred on ice for an additional 30 min. 
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Cells were disrupted by sonication for 5 min to complete the lysis. The resulting 
lysate was clarified by centrifugation at 13,000 rpm for 10 min and the supernatant 
was loaded onto a 5 mL HisTrap FF Ni-NTA column (GE Healthcare) pre-
equilibrated with lysis buffer using an AKTA Start FPLC (GE Healthcare). The 
column was washed with 2X PBS buffer (pH 8.0) containing 50 mM imidazole, and 
the bound protein was eluted using 2X PBS buffer (pH 8.0) containing 300 mM 
imidazole and 2 mM DTH. Fractions containing MftD proteins were immediately 
buffer exchanged into 2× PBS storage buffer (pH 8.0) containing 10% glycerol and 
2 mM DTH using PD-10 columns (GE Healthcare). The resulting volume 
containing MftD protein was concentrated using 30 kDa spin concentrators 
(Millipore). Tobacco etch virus (TEV) protease was added to the protein and 
incubated a room temperature for 3 h to hydrolyze the N-terminal His-tag. The 
protein/protease mixture was loaded onto a 5 mL HisTrap FF Ni-NTA column pre-
equilibrated with storage buffer. The flow through was collected, and the bound 
protein was eluted with 2X PBS (pH 8.0) containing 50 mM imidazole and 2 mM 
DTH. Fractions containing MftD proteins were pooled together and buffer 
exchanged into a fresh 2X PBS storage buffer (pH 8.0) containing 10% glycerol 
using PD-10 columns (GE Healthcare). The resulting protein fraction was 
concentrated using 30 kDa spin concentrators and subjected to a final size 
exclusion chromatography purification step as described above. 
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2.22 Cloning, Expression, and Purification of MftD from 
Mycobacterium smegmatis mc2155.  
           The msmeg_1424 gene encoding for MftD from Mycobacterium smegmatis 
mc2155 (Uniprot: A0QSB) was cloned into pET28a vector using NdeI and XhoI 
restriction sites. The sequence verified msmeg_1424/pET28a plasmid was 
transformed into E. coli ArcticExpress (DE3) for protein expression. MsMftD 
proteins were expressed and purified as described above for MuMftD with 
thrombin being substituted for TEV. 
 
2.23 Flavin Determination in MftD.  
          To determine the type of flavin contained in MftD, 100 μL of 200 μM of the 
purified protein was first denatured by heating at 80 °C for 10 min. The denatured 
protein was centrifuged at 14000 rpm for 10 min to remove all precipitated proteins. 
The supernatant was pipetted into a 1.5 mL HPLC autosampler vial and analyzed 
by reverse-phase chromatography on a Shimadzu Prominence-i LC-2030C HPLC 
using a Jupiter C 18, 5 μm, 4.6 X 250 mm column (Phenomenex) and 10 mM 
sodium phosphate monobasic, pH 5.5 (buffer A), and 90% methanol (buffer B) as 
the mobile phase. A linear gradient of solvent B from 0% to 35% was applied from 
2 to 7 min, which was followed by another linear gradient to 95% solvent B from 7 
to 15 min. A third gradient of solvent B from 95% to 100% was applied from 15 to 
17 min, after which solvent B was held constant at 100% from 17 to 19 min. This 
was followed by linear decrease to 100% solvent A from 19 to 22 min. Solvent A 
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was held constant for an additional 2 min to re-equilibrate the column before 
subsequent sample injections. Chromatograms were reported at 450 nm while 
monitoring wavelengths between 200 and 600 nm. Authentic samples of riboflavin, 
flavin mononucleotide (FMN), and flavin adenine dinucleotide were run as controls. 
 
 
2.24 Accessing the lability of MftD bound flavin mononucleotide 
(FMN).  
           HPLC analytical size exclusion chromatography was run on MftD protein 
under both aerobic and anaerobic conditions to assess the stability of MftD bound 
FMN. For the anaerobic assay, 100 µL of 200 µM purified protein containing 3 mM 
DTH was centrifuged at 14000 rpm for 5 min in an anaerobic chamber. The 
supernatant was transferred into a 1.5 mL autosampler HPLC vial anaerobically 
and analyzed by reverse-phase chromatography on a Shimadzu Prominence-i LC-
2030C HPLC using a BioSep-SEC-S 2000, 5 µm, 7.8 x 300 mm column 
(Phenomenex) and anaerobic PBS buffer pH 8.0 (Buffer A) as the mobile phase. 
Isocratic elution was applied, and chromatograms were reported at 280 nm for 
MftD and 450 nm for FMN while monitoring absorbance between 200 and 600 nm. 
The same procedure was repeated for the aerobic assay except MftD was oxidized 
by exposing it air at room temperature for 1 h and this was confirmed by a color 
change from colorless to deep yellow of the protein and an increase in 450 nm 
absorbance of UV spectrum. The mobile phase (PBS pH 8.0) was made aerobic 
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by purging with air for 30 min. Biorad Gel Filtration Standards containing protein 
standards for 670 kDa (thyroglobulin), 158 kDa (γ-globulin), 44 kDa (ovalbumin), 
17 kDa (myoglobin) and 1.35 kDa (vitamin B-12) were used to prepare a standard 
curve. 
 
2.25 AHDP Modification Reactions 
           AHDP modification reactions were conducted in volumes of 200 μL under 
aerobic and anaerobic conditions and contained 50 mM sodium phosphate (pH 
8.0) as the reaction buffer. Consecutively, 100 μM MftD, 200 μM FMN, and 100 
μM AHDP were added, and the reactions were incubated under aerobic and 
anaerobic conditions for 12 h. Control reactions were set up in a similar manner 
except buffer was substituted for individual reagents, protein, or substrate. 
Reactions were subsequently filtered through 0.2 μm spin columns to remove all 
precipitated proteins. The supernatant was pipetted into 300 μL autosampler 
HPLC vials and injected directly into a reverse-phase HPLC and analyzed as 
described above. New peaks were isolated, lyophilized, and analyzed by NMR and 
HRMS. 
 
2.26 Oxygen Requirement for MftD Reaction with AHDP  
           To investigate the dependence of MftD catalysis on oxygen, a total of 200 
μL of MftD reaction was set up under anaerobic conditions as follows. To the 
reaction buffer containing 2 × PBS (pH 8.0) were added consecutively 10 mM 
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glucose and 10 μM glucose oxidase followed by incubation at room temperature 
for 10 min to deplete oxygen from the buffer. Sequentially, 100 μM MftD, 200 μM 
FMN, and 200 μM were added to the reaction followed by an additional 12 h 
incubation period at room temperature. Reactions were filtered through 0.2 μm 
spin columns to remove all precipitated proteins. The supernatant was pipetted 
into 300 μL autosampler HPLC vials and injected directly into a reverse-phase 
HPLC system. HPLC analysis was carried out as described above 
 
2.27 Assessing for MftD activity with NAD+ 
           To assess if NAD+ could serve as the final electron acceptor in MftD 
reaction with AHDP, a total of 200 µL reaction was set up anaerobically as follows. 
To a reaction buffer containing 2 x PBS (pH 8.0) was added consecutively10 mM 
glucose and 10 µM of glucose oxidase (GOX) followed by incubation at room 
temperature for 10 min to deplete oxygen from the buffer. Subsequently, 100 µM 
of MftD, 200 µM of FMN, 200 µM of AHDP and 1 mM NAD+ were added stepwise 
to the reaction followed by an additional 12 h of incubation period at room 
temperature. Reactions were filtered through 0.2 µm spin columns to remove all 
precipitated proteins. The supernatant was pipetted into 300 µL autosampler 
HPLC vials and injected directly onto a reverse-phase HPLC system. HPLC 
analysis was carried out as described above. 
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 2.28 18O Isotope Labeling of PMFT 
           To determine the source of oxygen atom incorporated into the product of 
MftD catalysis, reactions were carried out in either 18OH2 or 18O2. For reactions 
carried out in 18OH2, a buffer solution of 25 mM ammonium acetate was first 
prepared by lyophilizing 500 μL of the buffer solution to powder and resuspending 
into an equal volume of 18OH2 (PET grade, Sigma-Aldrich). Reactions consisted of 
90 μL of 18OH2 buffer, 100 μM MftD (5 μL), 200 μM FMN (1 μL), and 100 μM AHDP 
(4 μL). Following a 1 h aerobic incubation at room temperature, the reaction was 
analyzed by HRMS by direct infusion onto a Thermo Scientific Q Exactive. 
Reactions carried out in the presence of 18O2 proceeded similarly but were 
performed in 16OH2 buffer that was bubbled with 18O2 for 5 min prior to the addition 
of MftD. A control reaction was performed to monitor the back-exchange of labeled 
oxygen. To do so, 16O-PMFT was incubated in 18OH2 buffer for 60 min prior to 
analysis by HRMS. 
 
2.29 Electrochemical Characterization of PMFT 
           To determine the redox potential of PMFT, a 5 mg/mL suspension of 
functionalized SWCNTs was made by dispersing 50 mg of the nanotubes in 10 mL 
of dimethylformamide and sonicating in an ultrasonic bath for 1 h to obtain a 
uniform suspension. Glassy carbon electrodes were polished with 0.05 μm 
alumina on nylon and microbroth polishing pads. The electrode was sonicated in 
10 mL of water in an ultrasonic bath for 5 min followed by 10 mL of ethanol for an 
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additional 5 min and allowed to thoroughly dry at room temperature. The dried 
electrode was coated with 20 μL of the SWCNTs suspension and allowed to dry at 
room temperature. This was repeated two more times allowing for thorough drying 
in between casts. The dried SWCNTs-modified glassy carbon electrode was 
incubated in phosphate buffer (pH 7.0) as control or in phosphate buffer (pH 7.0) 
containing 500 μM PMFT for 3 h prior to running cyclic voltammetry (CV) 
experiments. A conventional three-electrode system was used in a water-jacketed 
glass cell. The counter electrode was platinum wire, and Ag/AgCl was the 
reference electrode. CV measurements were carried out in a Coy Lab anaerobic 
chamber using a CHI 600E Series electrochemical analyzer. Measurements were 
recorded at 0.05 V/s with a potential sweep window of +0.2 to −0.8 V at 22 °C. 
 
2.30 Cloning, Expression, and Purification of Carveol Dehydrogenase 
(CDH) from Mycobacterium smegmatis mc2155 
          The msmeg_1410 gene sequence encoding CDH from M. smegmatis 
mc2155 (Uniport: A0QSA5) was cloned into pET28a using NdeI and HindIII 
restriction sites. The sequence verified msmeg_1410/pET28a plasmid was 
transformed into the E. coli BL21 star (DE3) and grown overnight at 37 °C in 50 
mL of LB containing 50 μg/mL of kanamycin. The overnight culture was used to 
inoculate 4 L of LB growth medium containing 50 μg/mL of kanamycin. The culture 
was incubated at 37 °C with shaking at 200 rpm until an OD600 of ∼0.6, at which 
point MsCDH production was induced by addition of IPTG to a final concentration 
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of 1 mM and allowed to grow overnight at 20 °C with shaking at 200 rpm. The cells 
were harvested by centrifugation at 7000 rpm for 10 min, and the pellet was 
resuspended in 5 times pellet mass of lysis 50 mM MOPS buffer (pH 7.0) 
containing, 250 mM NaCl and 30 mM imidazole. To the suspension were added 
0.1 mg/g of lysozyme, 0.1 mg/g of DNase, and 1% w/v 3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulfonate (CHAPS), and the mixture was stirred for 
30 min. Cells were disrupted by sonication for 5 min on ice to complete the lysis. 
The resulting lysate was clarified by centrifugation at 13000 rpm for 10 min, and 
the supernatant was loaded onto a 5 mL HisTrap HP Ni-NTA column pre-
equilibrated with lysis buffer using an AKTA Pure FPLC. The column was washed 
with 50 mM MOPS buffer (pH 7.0) containing 250 mM NaCl and 30 mM imidazole, 
and the bound protein was eluted using 50 mM MOPS buffer (pH 7.0) containing 
250 mM NaCl and 300 mM imidazole. Fractions containing MsCDH proteins were 
pooled together and immediately buffer exchanged into 50 mM MOPS storage 
buffer (pH 7.0) containing 250 mM NaCl and 10% glycerol using a HiPrep 26/10 
desalting column. The resulting volume of protein was concentrated using 10 kDa 
spin concentrators. Thrombin protease was added to the concentrated protein and 
incubated at room temperature for 1 h to cleave off the N-terminal His-tag. The 
protein/protease mixture was loaded onto a Superdex 200 10/300 GL analytical 
size exclusion chromatographic column using an AKTA Pure FPLC. The mobile 
phase was storage buffer containing 50 mM MOPS (pH 7.0), 250 mM NaCl, and 
10% glycerol at a flow rate of 1.0 mL/min. Protein peaks were collected and 
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concentrated using 10 kDa spin concentrators. The concentrated protein was 
aliquoted into 1.5 mL vials, flash-frozen in liquid nitrogen, and stored at −80 °C 
until use. 
 
2.31 Monitoring MsCDH UV Vis Spectral Changes in the Presence of 
PMFT 
           To determine if PMFT could be used as a cofactor by MsCDH for carveol 
modification, a UV spectroscopic assay was performed using Shimadzu TCC-
240A UV−visible spectroscopy as follows. An initial UV absorbance spectrum of 
200 μL reaction buffer containing 50 mM MOPS (pH 7.0), 250 mM NaCl, 10% 
glycerol, and 150 μM MsCDH was taken from 190 to 500 nm. Following the initial 
scan, 30 μM PMFT was added to MsCDH and incubated for 5 min, and the 
UV−visible spectra were measured. This was repeated until a final concentration 
of 150 μM PMFT was achieved. A control experiment was carried out using the 
same procedures but with NADH free in solution. 
 
2.32 MsCDH-Carveol Modification Reactions. 
           Carveol dehydrogenase modification reactions were conducted in a total 
volume of 200 μL containing 50 mM MOPS buffer (pH 7.0), 250 μM NaCl, 10% 
glycerol, 100 μM MsCDH, 500 μM carveol, and 500 μM PMFT. The reaction was 
incubated at room temperature for one hour. Control reactions were set up in a 
similar fashion except buffer was substituted for individual reagents, protein, or 
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substrate. Reactions were filtered through 3 kDa spin columns to remove all 
precipitated proteins. The supernatant was pipetted into 300 μL autosampler 
HPLC vials and injected directly onto a reverse-phase HPLC system. The HPLC 
analysis was as described above and UV absorbance readings were monitored 
between 200 and 400 nm. 
 
2.33 Stopped Flow Spectrophotometry.  
           A DX.17MV sequential stopped-flow spectrometer (Applied Photophysics, 
Leatherhead, UK) with a 3 ms deadtime was used to measure the single turnover 
oxidation experiments of MsCDH by PMFT and DCPIP. All reactions were carried 
out in 50 mM Hepes, pH 7.0, 250 mM NaCl, and 10% glycerol. For reactions with 
PMFT, the absorbance of the MsCDH bound NADH was monitored at 340 nm (Δε 
NADH 340 nm = 6.22 mM−1 cm−1). For reactions with DCPIP, the absorbance of 
the oxidant was monitored at 600 nm (Δε DCPIP 600 nm = 20.7 mM−1 cm−1). 
Reactions were set up so that the final concentrations were 160 μM MsCDH and 
25 or 50 μM PMFT, or 22 or 60 μM DCPIP. Reactions were run in triplicate at each 
concentration, averaged, and fitted to a single exponential decay or linear 
equations using the accompanying software. 
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CHAPTER THREE: RESULTS 
3.1 Identification of Conserved Cysteines in MftC 
           To identify possible cysteine residues involved in the coordination of [Fe-S] 
clusters in MftC, a bioinformatic analysis was carried out on all probable MftC 
homologues obtained from a BLAST query of the Uniprot database. From the 
BLAST, a total of 625 putative MftC sequences were retrieved and aligned, and 11 
cysteines were found to be strictly conserved. Based on their sequence-wise 
location and residue spacing, Cys30, 34, and 37 were assigned as the RS ligands 
(characteristic CX3CXɸC sequence motif). In addition to the RS sequence motif, 
residues Cys251, 258, 269, 310, 313, 319, 323, and 341 were also found to be 
strictly conserved among all 625 species (characteristic CX9-15GXC-gap-
CX2CX5CX3C-gap-C motif of the SPASM domain) (Figure 3.1). These last eight 
cysteine residues are expected to reside in the C-terminal SPASM domain and 
could bind one or two auxiliary [Fe−S] clusters. The conserved cysteine residues 
were then mapped onto a homology model of MftC that was generated on the basis 
of the structures for anSME (PDB ID: 4K36) (117), CteB (PDB ID: 5WHY) (83) or 
SuiB (PDB ID: 5V1T) (110). In the representative overlay between the modeled 
MftC and the parent anSME (sequence identity ∼25%) shown in Figure 3.2A, the 
predicted RS binding residues Cys 30, 34, and 37 align accordingly with the 
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corresponding RS binding motif of anSME. Similarly, the modeled MftC residues 
Cys 310, 313, 319, and 341 align well with those from anSME involved in ligating 
the Aux II cluster. Of the remaining four modeled MftC Cys residues, only residues 
269 and 323 overlay well with the Cys residues of anSME involved in binding the 
Aux I cluster. Residue Cys 251 is modeled in the vicinity of the Aux I cluster of 
anSME, but the modeled residue Cys 258 is located in the second shell around 
the Aux I cluster of anSME (Figure 3.2A). All models generated for MftC provided 
similar findings (Figure 3.2 B & C, sequence identities ∼20%). The poor overlay of 
two of the four Cys residues used to bind Aux I is likely due to the low sequence 
similarity, and neither exclude nor confirm binding of a cluster in the Aux I position 
in MftC.  
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Figure 3.1 Multiple sequence alignment of MftC visualized by Weblogo.  The probability of a 
residue in a position is indicated on the y-axis. Cysteine residues found to be strictly conserved 
were colored by predicted cluster binding (red – RS cluster, blue – Aux I cluster, and magenta – 
Aux II cluster) and numbered according to the M. ulcerans MftC amino acid sequence. 
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Figure 3.2  The model of MftC (grey), generated by Phyre 2.0.  MftC was modeled on the 
structure of (A) AnSME (PDBID: 4K36), (B) CteB (PDBID: 5WHY) and (C) the SuiB (PDBID: 5V1T) 
using one-to-one threading on phyre2. when overlain with the same CteB (green) or SuiB (cyan) 
structure implies that three [4Fe-4S] could be bound. The blowout figures show the cysteine 
residues around the RS cluster (red box), the Aux I cluster (blue box), and the Aux II cluster 
(magenta box). 
 
 
 
 
 
3.2 Generation of Soluble MftC Single- and Multiple Point Cysteine 
Variants.  
           To gain insights into the role of the auxiliary clusters in MftC catalysis and 
to identify the Cys residues involved in binding of the clusters, Ala variants of MftC 
were constructed. Using the bioinformatic information described above, Cys 
residues were systematically replaced with Ala to generate soluble RS KO, Aux I 
KO, and Aux II KO variants. For the RS KO variant, Cys30 and Cys37 were 
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mutated to generate the C30A/C37A double mutant. The triple mutant 
C30A/C34A/C37A was insoluble. For the Aux I KO variant, only the single mutants 
C269A and C323A were soluble. Both the C251A single mutant and the double 
C269A/C323A mutant resulted in insoluble protein. The C258A variant did not 
impact protein solubility or MftC activity and was not considered an important 
mutation. Since the C269A and C323A variants were found to have identical 
enzymatic activity and since C323A could be produced in larger quantities, the 
C323A variant was used as in all experiments as the Aux I KO. To make the Aux 
II KO, Cys310 and Cys341 were mutated to generate the C310A/C341A double 
mutant. Additional mutations of the Aux II site led to insoluble protein. The purity 
of the MftC variants were checked by SDS-PAGE and size exclusion 
chromatography (SEC) (Figure 3.3). For all variants of MftC, the proteins were 
purified to near homogeneity as determined by SDS-PAGE (Figure 3.3A). In 
addition, the SEC profile of MftC variants showed a major peak at a retention time 
consistent with ∼42 kDa (Figure 3.3B). This suggests that the RS KO, Aux I KO, 
and Aux II KO had a minimal effect on the oligomeric state of MftC. 
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Figure 3.3 Characterization of purified MuMftC proteins.  (A) An SDS-PAGE gel containing a 
protein ladder (Gold Bio Blue Stain Plus) shows that all MftC variants have been purified to near 
homogeneity and that they are all approximately 42 kDa. (B) The chromatogram of size exclusion 
chromatography experiments monitoring protein absorbance at 280 nm shows that MftC (black), 
RS KO (red), Aux I KO (blue), and the Aux II KO (violet) are predominantly in the monomeric state. 
Protein standard elution volumes for thyroglobulin (670 kDa), -globulin (158 kDa), oval albumin 
(42 kDa) and myoglobin (17 kDa) are indicated by black arrows. 
 
 
3.3 MftC Contains Three [4Fe−4S] Clusters. 
           UV-vis spectroscopic and iron-sulfur quantification assays from previous 
experiments suggested that MftC contains [Fe−S] clusters; however, the exact 
number and configuration (e.g., [4Fe− 4S] vs [2Fe−2S]) of the clusters have not 
been established (97, 98). To address this, Mössbauer spectroscopic experiments 
were carried out of MftC and MftC variants to gain independent additional insights 
into the chemical nature and number of [Fe−S] clusters. The 4.2 K/78 mT 
Mössbauer spectrum of the as-isolated wild-type MftC is shown in Figure 3.4 and 
can be best analyzed considering two quadrupole doublets, which account for 88% 
of the total iron in the sample. The dark green shaded doublet has an isomer shift 
of δ = 0.26 mm/s and quadrupole splitting of ΔEQ = 0.55 mm/s, parameters that 
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are characteristic of all-ferric [2Fe−2S] clusters in their 2+ state. The light-green-
shaded doublet has an average isomer shift of δ = 0.45 mm/s and an average 
quadrupole splitting of ΔEQ = 1.01 mm/s, parameters that are characteristic of 
valence delocalized Fe2+−Fe3+ cysteine-coordinated pairs in oxidized [4Fe−4S]2+ 
clusters. The mismatches between the summations of the theoretical spectra with 
the experimental data reveal the presence of a minor and poorly defined sub 
spectrum (∼10% intensity), which we attribute to nonspecifically bound iron. 
Considering the number of Fe ions per cluster and those obtained from elemental 
analysis the as-isolated MftC sample contains 0.67 [2Fe−2S]2+ clusters and 0.61 
[4Fe−4S]2+ clusters per polypeptide, respectively. 
                       Since the as-purified protein already contains an appreciable number 
of [Fe−S] clusters, the protein employed for Mössbauer analysis to probe the 
number of clusters was chemically reconstituted with 2 equivalence of [Fe−S] 
centers (see Methods 2.7). The 4.2 K/78 mT Mössbauer spectrum of this sample 
is shown in Figure 3.4 (bottom) and can be best analyzed considering a single 
quadrupole doublet that accounts for 92% of the total iron in the sample. The light 
green shaded quadrupole doublet has an isomer shift of δ = 0.45 mm/s and a 
quadrupole splitting of ΔEQ = 1.11 mm/s, parameters consistent with the presence 
of oxidized [4Fe− 4S]2+ clusters. The remaining small broad absorption in the 
spectrum accounts for ∼8% and corresponds to nonspecifically bound iron. There 
are no signals detectable for [2Fe−2S]2+ clusters, suggestive that their presence in 
the as-purified MftC could be an oxidative byproduct. After correction for the 
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number of Fe ions per cluster and elemental analysis, the sample was found to 
contain 2.7 ± 0.15 [4Fe−4S]2+ clusters per polypeptide confirming that that MftC 
contains three [4Fe−4S]. This finding was further corroborated by data from the 
quantification of iron and sulfur in the chemically reconstituted wildtype MftC 
protein (Table 1). Taken together, these results provide direct evidence that MftC 
contains thee [4Fe-4S] clusters, however more information regarding the crystal 
structure of MftC is required to determine the coordination state (open versus full 
ligation) of the two Auxiliary clusters. 
 
Figure 3.4 Mössbauer spectra of the as-purified and chemically reconstituted wildtype 
MuMftC at 4.2 K.  (Top) The spectrum of the as-isolated MftC (black) consists of a quadrupole 
doublet corresponding to the presence of [2Fe−2S] clusters (dark green highlight) and [4Fe−4S] 
clusters (light green highlight). The overall simulation is overlaid on the experimental spectrum as 
a black solid line. (Bottom) The spectrum of the chemically reconstituted with 2 equivalence of 
[Fe−S] clusters MftC (black) consists of a single quadrupole doublet corresponding to the presence 
of [4Fe−4S] clusters. The spectra were recorded in the presence of a small external magnetic field 
(0.078 T), applied parallel to the orientation of the γ beam. 
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 WT MftC MftC RS KO MftC Aux I KO MftC Aux II KO 
Iron 10.0 ± 0.2 7.4 ± 1 8.8 ± 0.2 8.2 ± 0.1 
Sulfide 8.1 ± 0.1 7.9 ± 0.1 10.0 ± 0.4 7.7 ± 0.1 
Table 1 Iron and sulfur quantification for reconstituted MftC proteins. 
 
3.4 All Three [Fe−S] Clusters Are Required for MftC Modification of 
MftA 
           Having demonstrated that MftC contains three [4Fe-4S] clusters, we next 
set out to investigate the role of the Aux I and Aux II clusters in MftC catalysis. This 
was done by carrying out activity assays for the RS KO, Aux I KO, and Aux II KO 
mutants. Reactions containing the appropriate components (see the Methods and 
Materials) were analyzed by reverse phase HPLC, monitoring the absorbance at 
260 nm (SAM cleavage) or 280 nm (peptide modification). As shown in Figure 3.5, 
Wildtype MftC catalyzed the reductive cleavage of SAM to form dAdo and further 
converted the substrate MftA to MftA*. Conversely, the RS KO could neither cleave 
SAM nor modify MftA, consistent with the successful knockout of the RS cluster. 
Activity assays for Aux I and Aux II KOs also provided insightful results. Both Aux 
I and Aux II KOs were capable of catalyzing the reductive cleavage of SAM to form 
dAdo (Figure 3.5A), suggesting that the RS cluster remained intact and in an active 
conformation in the mutated proteins. However, when assayed against MftA, both 
Aux I and Aux II KOs were incapable of converting MftA to MftA* or MftA** (Figure 
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3.5B). This suggests that the Aux I and Aux II are required for catalysis, consistent 
with results shown for QhpD, AnSME, SCIFF, and PqqE (74, 110, 158, 191). 
 
 
Figure 3.5 Activity assays of wildtype and mutant MuMftC.  Reactions consisting of (A) 2 mM 
SAM, 10 mM DTT, 2 mM DTH, and 100 μM of the MftC variant or (B) 2 mM SAM, 10 mM DTT, 2 
mM DTH, 100 μM MftA, 100 μM MftB, and 100 μM of the MftC variant suggest that Aux I and Aux 
II clusters are not required for SAM turnover and that all three clusters are required for MftA 
modification. 
 
3.5 Protein Film Electrochemistry Measured the Midpoint Potentials 
for All Clusters in MftC. 
           MftC catalyzes both oxidative and redox neutral reactions in the same 
active site. This unique ability of MftC suggests that the Auxiliary clusters could 
partake in the reaction through an electron transfer mechanism. To determine if 
the redox potentials of the Auxiliary clusters could accommodate the reversible 
electron transfer between the clusters, protein-film electrochemistry was carried 
out on MftC and its variants. Wild-type MftC was noncovalently adsorbed onto a 
plan-edge graphite electrode using multiwalled carbon nanotubes as a co-
adsorbent. A single and broad feature in the cyclic voltammogram for wild-type 
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MftC was observed between −425 and −600 mV (Figure 3.6A). This suggests that 
the three [4Fe−4S] clusters have similar reduction potentials that appear as a 
single envelope when summed up. The envelope signal was fitted using QSoas 
software, and three, one electron transfers with reduction potentials of ∼ −550, 
−500, and −460 mV vs SHE were extracted (Table 2) (192). The three reduction 
potentials represent three redox active species and are expected to represent each 
of the three [4Fe−4S] clusters found on MftC. To resolve which reduction potential 
belonged to which cluster, the same analysis was conducted on the RS KO and 
Aux II KO. In experiments containing the RS KO, fitted data suggest that two redox 
active species, with reduction potentials of −507 and −502 mV vs SHE, are present 
(Figure 3.6B and  Table 2) Notably, the highest potential of ∼ −460 mV was no 
longer apparent, suggesting that this potential belongs to the RS cluster. It 
remained unclear which of the two remaining signals belong to the Aux I or Aux II 
cluster. To clarify this, the cyclic voltammogram for the Aux II KO variant was also 
acquired and fitted. The fitted data from this experiment indicated that two redox 
active species, with reduction potentials of −520 and −454 mV vs SHE, were 
present (Figure 3.6C and Table 2). The reappearance of the ∼ −460 mV species 
further suggests that the midpoint potential for the RS cluster is indeed ∼ −460 
mV. Additionally, the remaining signal of −520 mV could be assigned to the Aux I 
cluster. It is likely that the −520 mV species found in the Aux II KO data set 
corresponds to the −550 mV species found in the wild-type MftC data set. 
Therefore, the resting state reduction potentials measured for MftC could be 
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assigned as the following: ∼ −460 mV, RS cluster; −550 mV, Aux I cluster; −500 
mV, Aux II cluster. These potentials are similar to those found for the only other 
RS-SPASM protein measured to date, SCIFF maturase. SCIFF maturase 
catalyzes the formation of intramolecular thioether bonds on its precursor peptide 
and also contains three [4Fe− 4S] clusters (74). Similar to MftC, the reduction 
potentials measured for the three [4Fe−4S] clusters on SCIFF maturase were 
−490, −540, and −585 mV vs SHE (193). 
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Figure 3.6  Voltammetry of MftC and variants measured at pH 7.5 and 4 °C.  (A) Cyclic 
voltammogram measured with a scan rate of 50 mV/s for wild-type MftC (solid line), fitting for three, 
one electron transfers (dotted line), and EPG baseline (dashed line). Square wave voltammograms 
measured with a frequency of 10 Hz and an amplitude of 20 mV for (B) wild-type MftC (solid line), 
(C) RS KO, and (D) Aux II KO with EPG baselines (dashed line). Additional CV data of (E) the RS 
KO and (B) the Aux II KO constructs. 
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Variant Em,1 (mV vs SHE) Em,2 (mV vs SHE) Em,3 (mV vs SHE) 
Emid, (mV vs SHE) 
WT MftC - 549 - 499 - 458 - 489 
RS KO - 507 - 502  - 484 
Aux II KO - 520  -454 - 475 
Table 2 Reduction potentials and midpoint potentials for the RS, Aux I, and Aux II 
[4Fe−4S]2+/1+ clusters in MftC 
 
          Taken together, these results suggest that MftC contains three [4Fe-4S] 
clusters, all of which are required for catalysis. In addition, the redox potentials of 
these clusters are within -100 mV apart, particularly the Auxiliary clusters which 
are within 50 mV apart. The similarity of the redox potentials of the auxiliary 
clusters of MftC could allow for the reversible electron transfer between the 
clusters, hence the ability of MftC to catalyze both oxidative and redox neutral 
reactions in the same active site. Based on this, a revised mechanism for MftC 
catalysis is proposed. This mechanism involves an electron being shuttled from 
the substrate into the Aux I cluster to form a benzenone intermediate. The Aux I 
cluster subsequently shuttles this electron into the Aux II cluster to complete the 
first step of MftC catalysis (Figure 3.7 black).  In the second step, the electron is 
back into the reaction to quench the substrate radical to complete MftC catalysis 
resulting in the formation of MftA* (Figure 3.7 blue). This mechanism fits the ability 
of MftC to redox flip, however, there is only one caveat. That is, in the absence of 
the Aux II cluster, we should expect accumulation of the intermediate MftA** in 
MftC peptide modification assays, however, that is not the case (Figure 3.5B). 
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Instead, we observed aborted catalytic reaction of MftC, which could suggest that 
the Aux II cluster is playing some structural role in MftC and without it, the 
catalytically structural scaffold of MftC is distorted. It should be noted that without 
additional information regarding the crystal structure of MftC, this is nothing more 
than speculation. 
 
Figure 3.7 Revised mechanism for MftC catalysis. All three clusters in MftC are required for 
catalysis. An electron is shuttled from Aux I to Aux II during the decarboxylation step (black) and 
this electron is shuttled back to quench the substrate radical in the carbon-carbon crosslink step 
(blue).    
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3.6 MftE is a member of the creatinine amidohydrolase family 
(IPR003785)  
           MftE is a member of the creatinine amidohydrolase family of proteins (185). 
This is a large protein family consisting of more than 11000 protein sequences 
annotated as IPR003785. Creatinine amidohydrolases are widely distributed 
binuclear Zn2+ enzymes responsible for the hydrolysis of creatinine to form creatine 
(194, 195). Within this family are the FAPy deformylase and mycofactocin 
peptidase MftE subfamilies. Interestingly, both subfamilies are associated with 
cofactor biosynthesis. While MftE is associated with mycofactocin biosynthesis, 
FAPy deformylase on the other hand is involved in the Fe2+-dependent 
deformylation of 2-amino-5- formylamino-6-ribosylamino-4(3H)-pyrimidinone 5′-
monophosphate during the biosynthesis of the redox cofactors F0 and F420 (196). 
To observe the relationship between the mycofactocin peptidase, MftE, and the 
remaining members of the amidohydrolase fold family, a sequence similarity 
network (SSN) was generated for the IPR003785 family using the Enzyme 
Function Initiative-Enzyme Similarity Tool (ESIEST) (190). The analysis, based on 
6279 Uniref 90 sequences, generated a network consisting of 3432 nodes where 
each node represents a set of protein sequences that are 50% identical (Figure 
3.8). Notably, the mycofactocin (green, 43 sequences) stand out from the central 
creatinine amidohydrolase clusters (1735 sequences). Indeed, the majority of 
sequences within the network belong to uncharacterized clusters that are 
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independent of the creatinine amidohydrolase central clusters, suggesting that this 
family of proteins may have evolved to hydrolyze a variety of substrates. 
 
 
Figure 3.8 A sequence similarity network for MftE.  A sequence similarity network for the 
creatinine amidohydrolase family (IPR003785) shows the divergence of the mycofactocin 
peptidase (green) and the FAPy deformylase (cyan) from the main body of creatinine 
amidohydrolases. 
 
 
3.7 Characterization of purified MftE. 
           To investigate the activity of MftE in the biosynthesis of mycofactocin, the 
MftE protein from M. ulcerans was cloned into, overexpressed in, and isolated from 
E. coli. Recombinant MftE was purified to >95% purity, as determined by SDS-
PAGE (Figure 3.9A).  The purified protein showed high homogeneity as 
determined by size exclusion chromatography, with >95% of the total protein 
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appearing at retention a time  consistent with that of an octamer (Figure 3.9 C).  
As described above, MftE is a member of the metal-binding creatine 
amidohydrolase protein fold family and was previously shown to bind zinc and iron 
(185).  However, efforts to fully reconstitute the protein with iron and zinc and their 
influence on catalysis of MftE were not reported. To address this, metal 
quantification assays of as-purified and reconstituted MftE were carried out.  
Consequently, ICP-MS analysis of the as-purified MftE revealed that it binds 0.51 
± 0.01 mol equivalents of Zn2+ and 0.10 ± 0.01 mol equivalents of Fe2+, consistent 
with the previously reported values (185). Following reconstitution with Zn2+, MftE 
was found to bind 0.57 mol equivalents of Zn while maintaining ∼0.10 mol 
equivalents of Fe. Likewise, when Fe2+ was added, MftE was found to bind 0.70 ± 
0.02 mol equivalents of Fe and maintained 0.15 ± 0.01 mol equivalents of Zn. Upon 
reconstitution with both Fe2+ and Zn2+, MftE was found to bind 0.71 ± 0.01 mol 
equivalents of Fe and 0.55 ± 0.01 mol equivalents of Zn per polypeptide chain 
(Table 3), that is one atom of Fe2+ and one atom of Zn2+ per polypeptide chain, 
similar to that of FAPy deformylase protein ArpB (196).  
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Figure 3.9 Characterization of MftE proteins. An SDS-PAGE gel of MftE from (A) M. ulcerans 
and (B) M. smegmatis shows that the protein is >95% pure and has a molecular weight of 
approximately 27 kDa. (C) The chromatogram from the size exclusion chromatography while 
monitoring absorbance at 280 nm shows that majority of the purified protein migrates as an octamer 
with a molecular weight of 230 kDa. Protein standard elution volumes for thyroglobulin (670 kDa), 
γ-globulin (158 kDa), ovalbumin (44 kDa), myoglobin (17 kDa) and vitamin B-12 (1.35 kDa) are 
indicated by the black arrows 
 
 
Sample Fe2+ eq Zn2+ eq 
As-purified MftE 0.10 ± 0.01 0.51 ± 0.01 
MftE + Fe(NH3)SO4 0.70 ± 0.02 0.15 ± 0.01 
MftE + ZnCl2 0.08 ± 0.01 0.57 ± 0.01 
MftE + Fe(NH3)SO4 and 
ZnCl2 
0.71 ± 0 .01 0.55 ± 0.01 
Table 3 ICP-MS quantification of metal ions in MftE. Analysis of metal iron content of as-purified 
and reconstituted MftE shows that the protein copurifies with both iron and zinc.  
 
 
 
3.8 MftE is selectively active towards MftA* 
            Since multiple products are produced from MftC reaction, a new question 
regarding the correct precursor for mycofactocin biosynthesis has arisen. To 
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address this question, we set out to probe the activity of MftE towards MftA* and 
MftA** or both. Previous studies have demonstrated that MftE from Mycobacterium 
smegmatis hydrolyzes MftA** to produce Val-p-(2-aminoethenyl)phenol and the 
remaining truncated MftA peptide (185). However, these results were largely 
dependent upon difficult HPLC−ESI-MS analysis of a complex mixture and with 
the inability to distinguish the substrate (e.g., MftA* vs MftA**) or the structure of 
the product. Additionally, the mass estimated for the small molecule is consistent 
with the hydrolyzed products from both MftA* and MftA**. To circumvent these 
obstacles, MftA* and MftA** were separately purified from reaction mixtures 
containing MftA, MftB, MftC, dithiothreitol (DTT), SAM, and dithionite (DTH), as 
previously described (Figure 3.10A) (99), and individually used in reactions with 
MftE. Purified and chemically reconstituted MuMftE was incubated with MftA, 
MftA*, or MftA** for 3 h at room temperature and the reaction mixture was analyzed 
by HPLC while monitoring the absorbance of tryptophan and tyrosine at 280 nm. 
In the control experiment, MftA eluted at ∼13 min (Figure 3.10B, black) and the 
addition of MuMftE to MftA did not result in a significant change in the 
chromatogram (Figure 3.10B, gray). Likewise, when MuMftE was added to MftA**, 
no significant change was observed in the chromatogram (Figure 3.10B, blue and 
light blue). However, the addition of MuMftE to MftA* resulted in the formation of 
two new product peaks (12.5 and 13.9 min) with the concomitant disappearance 
of the MftA* peak (Figure 3.10B, red and orange).  
 104 
 
            To confirm that this activity was not unique to MuMftE, and to reconcile the 
different activities reported for MsMftE versus those being discussed in this 
dissertation, MftE from M. smegmatis was cloned into and purified from E. coli 
(Figure 3.9 B), and tested its substrate specificity towards MftA, MftA* and MftA**. 
The reaction mixtures were analyzed on HPLC in the same manner described for 
MuMftE. As expected, the HPLC chromatograms for the MsMftE reaction showed 
results similar to that of MuMftE (Figure 3.10C), indicating that AHDP is most likely 
the substrate for both Ms and MuMftE. To further probe the selectivity of MftE for 
its substrate, MuMftE was incubated with MftA* in the presence of equal amounts 
of MftA** and reaction mixture was analyzed by HPLC. The chromatogram for the 
reaction showed that MftE retained its activity toward MftA* (Figure 3.10D).  UV-
vis spectral analysis of the products of MftE reaction showed that the new peak at 
13.9 mins displayed absorption properties reminiscent of tyrosine (Tyr 30 of MftA*) 
while the peak at 12.5 mins was similar to that of the substrate MftA* (MftA (1-28) 
of MftA*). Taken together, these results demonstrate that MftE is highly specific for 
the substrate MftA* and does not recognize the unmodified peptide MftA or the 
intermediate MftA**. Therefore, we propose that MftA* is the correct precursor in 
mycofactocin biosynthesis. 
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Figure 3.10 HPLC chromatograms of MuMftC and MuMftE reactions.  (A) MftC reactions 
consisting of 2 mM SAM, 10 mM DTT, 2 mM DTH, and 300 μM of the MftC, 300 µM MftB and 300 
µM MftA. (B) MuMftE and (C) MsMftE reactions containing 50 μM MftA* and MftA** with and without 
50 μM MftE indicate that MftE preferentially hydrolyzes MftA* to form two new products with 
retention times of 12.5 and 13.9 min (orange). All MftE reactions were performed in the presence 
of 50 μM Zn2+ and 50 μM Fe2+. (D) MftE selectively cleaves MftA* in the presence of MftA**. (E) 
UV-vis spectra of the products of MftE reaction. (F) A one-pot reaction mixture of MftC and MftE 
containing 2 mM SAM, 10 mM DTT, 2 mM DTH, and 300 μM of the MftC, 300 µM MftB, 300 µM 
MftA and 300 µM MftE. 
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3.9 MftE requires iron (II) for catalysis. 
           Having found from ICP-MS analysis that MftE binds both Zn2+ and Fe2+, we 
next set out to determine the effects of these divalent cations on MftE catalysis. 
Initially, reactions were set up under steady state ([MftA*] ≫ [MftE]) conditions in 
the presence of 1 equivalent of Zn2+ and/or Fe2+ (Figure 3.11B); however, we 
observed that MftE catalyzes only single turnover reactions under these 
conditions. Attempts to modify reaction conditions to promote multiple turnovers 
(e.g., addition of ascorbate, DTT, Fe2+, or Fe3+) were unsuccessful (Figure 3.11A). 
Therefore, reactions were set up under single turnover conditions ([MftE] > [MftA*]) 
in the presence of Zn2+ and or Fe2+ and the reaction products were analyzed by 
HPLC. The relative integrated peak area of the substrate, MftA* was plotted versus 
time (Figure 3.11C), and the reaction rates were extracted from single-exponential 
decay fits and reported as kobs (Table 4). Under these conditions, the rate of 
hydrolysis for as-purified MftE is a modest 0.001 min−1. The addition of Zn2+ had 
limited effect on the reaction rate (kobs = 0.018 min−1), whereas the addition of Fe2+ 
increased the rate by >200-fold from 0.001 min-1 to 0.232 min−1. The addition of 
both Zn2+ and Fe2+ had approximately the same effect on the reaction rate as Fe2+ 
alone. The aggregated data suggests that Fe2+ is catalytically active in MftE and 
that Zn2+ could be playing an auxiliary role. The observations made here are 
consistent with those reported for AprB where the addition of Fe2+ increased the 
catalytic rate 10-fold (196). In ArpB, it was proposed that the addition of Fe2+ 
replaced the catalytically inactive Fe3+, resulting in an increased activity. However, 
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unlike MftE, ArpB is capable of multiple turnovers, which suggests that we are 
missing an important cofactor in our reactions. 
 
Protein kobs (min-1) 
As-purified MftE 0.001 ± 0.001 
MftE + Fe(NH3)SO4 0.018 ± 0.006 
MftE + ZnCl2 
MftE + Fe(NH3)SO4 + ZnCl2 
0.23 ± 0.04 
0.12 ± 0.01 
Errors are reported as the sum of squared errors. 
Table 4 Extracted initial reaction rates for MftE catalysis with the Addition of the Indicated 
Metals. 
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Figure 3.11 Screening of reaction conditions for MftE catalysis.  (A) HPLC chromatograms of 
various reaction conditions to increase multiple turnovers. All reactions were carried out under 
steady-state conditions. (B) Addition of Fe2+ and or Zn2+ to MftE reaction indicates Fe2+ enhances 
the reaction rate of MftE. (C) The time course reaction of MftE with MftA* in the presence of various 
metals indicate that complete hydrolysis of MftA* is achieved in the presence of Fe2+. 
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3.10 MftE hydrolyzes MftA* to form 3-amino-5-[(p-hydroxyphenyl) 
methyl]-4,4-dimethyl-2-pyrroli-dinone (AHDP). 
           Having demonstrated that MftE is specific for MftA*, we next set out to 
characterize the products of this reaction. To begin with, new peaks from HPLC 
analysis were isolated and analyzed by HRMS. First, the mass spectrum of MftA* 
shows an abundant species at m/z = 1111.85 ([M + H]3+ + H2O, theoretical m/z = 
1111.85) consistent with a 46 Da loss of mass from the unmodified peptide MftA 
(Figure 3.12A and B). The difference of 46 Da is indicative of the loss of 1C, 2O, 
and 2H, consistent with the decarboxylation of the C-terminal tyrosine and 
subsequent C−C bond formation between Val29 and Tyr30 as previously 
published (99). The mass spectrum of the 12.5 min peak from the MftE reaction 
showed a prominent species at m/z = 1550.21 ([M + H]2+). This mass is 217 Da 
lower than the mass of MftA* (Figure 3.12C), and the difference in mass is 
consistent with the loss of the last two residues on MftA* plus the addition of an 
OH from the hydrolysis of the Gly28−Val29 amide bond (theoretical [M + H]2+ m/z 
= 1550.21). The mass spectrum of the 13.9 min peak from the MftE reaction 
showed an abundant mass at m/z 235.1436 [M + H]+ (Figure 3.12D). This new 
mass is consistent with the mass of AHDP (theoretical ([M + H]+ m/z = 235.1441). 
These results demonstrate that MftE acts as a selective peptidase by hydrolyzing 
the amide bond between Gly28 and Val29 of MftA* to form two new products: MftA 
(residues 1−28) and, putatively, AHDP. To corroborate this finding, we turned to 
1H NMR to solve the structure of the two products from MftE reaction with MftA*. 
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The rationale for this experiment is that if MftE cleaves the last two residues of 
MftA*, we would expect to see the disappearance of the two aromatic doublet 
peaks from tyrosine in the 1H NMR spectrum of the cleaved peptide MftA (1−28). 
Indeed, the 1H NMR spectrum of MftA (1−28) shows the absence of the two-
tyrosine aromatic doublets at δ = 7.12 and 6.79 ppm when compared to the 1H 
NMR spectrum of MftA* (Figure 3.13A and B) (See Figure S 1A and B for full 
spectra). Currently, the only evidence of the existence of the AHDP precursor 
comes from deuterium labeling in reactions with MftC and limited 13C NMR 
experiments with MftA*. Therefore, we set out to determine the structure of the 
putative AHDP molecule by using 1H NMR, COSY, and 13C NMR techniques. To 
do so, submilligram quantities of the molecule were purified from one-pot reaction 
mixtures containing MftA, MftB, MftC, MftE, SAM, DTT, and DTH (Figure 3.10F). 
To obtain the 13C-enriched AHPD for 13C NMR experiments, MftA labeled with both 
13C9 and 15N-enriched tyrosine and 13C5- and 15N-enriched valine was used in the 
aforementioned one-pot reaction. Heavy MftA was produced via in vivo expression 
of the peptide in E. coli grown in M9 medium supplemented with the heavy amino 
acids. These procedures resulted in the heterogeneous incorporation of 13C into 
AHDP. One-dimensional 1H NMR analysis (Figure S 1C) of the putative AHDP is 
consistent with the structure containing a para-substituted aromatic (δ = 6.79 and 
7.14 ppm), two nonequivalent methyl groups (δ = 0.82 and 1.03 ppm), an isolated 
hydrogen near an amino group (δ = 3.31 ppm), two nonequivalent benzylic 
hydrogens (δ = 2.498 and 2.79 ppm), and a hydrogen within a substituted lactam 
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(δ = 3.56 ppm). COSY spectral analysis (Figure S 1E) indicates several crosspeak 
couplings between proton peaks. These include crosspeak couplings between 
aromatic hydrogens on C9−C10 (Figure 3.13C), and between aliphatic hydrogens 
on C7−C1 and C5−C1 (Figure 3.13D). Assignments of these couplings are 
highlighted in Figure 3.13E and are consistent with the proposed structure for 
AHDP. Additionally, 13C NMR analysis (Figure S 1D) provided the chemical shifts 
of the carbon signals that are consistent with the proposed structure for AHDP. 
The aggregated MS data and NMR data presented here are consistent with the 
product of the MftE reaction with MftA* being AHDP. 
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Figure 3.12 HRMS analysis of the products of MftA* reaction with MftE.  (A) The extracted ion 
chromatogram of M1W MftA consistent with a [M+2H]2+. (B) The extracted ion chromatogram of 
MftA* corresponding to a [M+3H]3+ + H2O. (C) The ion chromatogram of the remaining cleaved 
peptide MftA (1-28) corresponding to a [M+2H]2+. (D) The ion chromatogram of the dipeptide AHDP 
corresponding to a [M+H]1+. Simulated ion chromatograms are indicated in red and the 
experimental ion chromatograms are indicated in black. 
 
 113 
 
 
 
Figure 3.13 NMR spectral analysis of the reaction products of MftE.  1H NMR spectra of the 
aromatic regions of (A) MftA* and (B) MftA (1-28) showing the loss of the aromatic peaks at δ = 
7.12 and 6.77 ppm. (C) COSY NMR spectra of the aromatic regions showing cross couplings 
between the hydrogens on C9 and C9. (D) COSY NMR spectra of the lactam region showing 
important cross coupling peaks between the hydrogens on C7-C1 and C5-C1. (E) Structural 
representation of the results from COSY NMR. Cross-peak couplings are represented by thick 
bonds. 
 
            
           To decipher the reaction mechanism of MftE, we turned our attention to the 
members of creatininase amidohydrolase family. As described earlier, members 
of this family catalyze the hydrolysis of diverse array of substrates (197). They are 
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typically binuclear zinc metalloenzyme that play key roles in bacterial creatininase 
degradation. A search of the PDB database with the sequence of MftE 
revealed similarity to creatininase homologs whose structures are known. 
Sequence alignments (Figure 3.14A) and mapping of conserved residues of MftE 
onto the structures of a creatinine amidohydrolase (PDB ID 1Q3K) show that MftE 
retains the active site residues that bind the divalent cations (Figure 3.14B and C) 
(197). These divalent cation metals are used to activate water molecules and to 
stabilize the negatively charged oxyanion intermediate generated during catalysis 
reaction. Modeling studies suggest that the divalent cations interact with both the 
carbonyl of the peptide bond to be hydrolyzed and an active polar residue. This 
interaction  results in the polarization of the carbonyl group for subsequent 
nucleophilic attack (198).  As a member of the creatininase amidohydrolase family 
and on the basis of sequence conservation in the active site of MftE, a reaction 
mechanism similar to that of creatininase amidohydrolase has is proposed (Figure 
3.14D). This mechanism involves the coordination Fe2+ by both the carbonyl on 
Gly20 and an active site polar residue (e.g. Glu or Asp). This polarization results 
in the susceptibility of carbonyl bond to nucleophilic attack and subsequent bond 
cleavage (Figure 3.14D). However, it should be noted that without additional 
guiding information regarding the crystal structure of MftE, it is problematic to 
accurately predict the mechanism of MftE hydrolysis.  
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Figure 3.14 Sequence alignment and proposed mechanism of MftE catalysis  (A) Sequence 
alignment of MftE with known crystal Structures of members of creatininase amidohydrolase family. 
Highlighted in magenta are conserved residues in the active sites for binding metal ions. (B) 
structure of MftE (blue) modeled onto the creatinine amidohydrolase (PDBID: 1Q3K) (magenta). 
(C) structure of MftE showing the catalytic residues used to coordinate two Fe2+. (D) Proposed 
reaction mechanism for MftE hydrolysis. 
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3.11 MftD is a member of the FMN-dependent alpha-hydroxy acid 
oxidase family (IPR012133) 
 
            MftD is a member of the FMN- dependent alpha hydroxy acid oxidase 
family of proteins. This is a large protein family consisting of more than 25,000 
protein sequences annotated as IPR012133. This family includes notable 
members such as FMN-dependent lactate dehydrogenase and mandelate 
dehydrogenase. To observe the relationship between the mycofactocin system 
oxidoreductase and other members of this protein family, a sequence similarity 
network (SSN) was generated for the IPR012133 family using EFI-EST. From the 
analysis of 34,115 Uniref90 sequences, a network consisting of 2,215 nodes where 
each node represents a cluster of protein sequences that are 50% identical were 
generated. Interestingly, the SSN results showed the divergence of the 
mycofactocin system oxidoreductase (MftD) from the central alpha-hydroxy acid 
oxidase cluster (Figure 3.15, yellow). Clusters of other notable members such as 
mandelate dehydrogenase were found to also stand out from the central cluster. 
Members of the alpha-hydroxy acid oxidase family are known to use an FMN-
dependent ping-pong reaction mechanism for catalysis. In the first reductive half 
reaction, an alpha-hydroxy acid substrate is oxidized to an alpha-keto-acid 
resulting in the reduction of the enzyme-bound FMN. In the second oxidative half 
reaction, the flavin is re-oxidized by transferring an electron to an acceptor such 
us molecular oxygen to produce hydrogen peroxide (199). This commonality 
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among the FMN-dependent dehydrogenases led us to speculate that if 
mycofactocin is indeed a redox cofactor, then MftD could catalyze the molecular 
oxygen dependent oxidation of the phenyl ring of AHDP to generate the 
corresponding catechol with a redox active center which is not apparent in AHDP. 
 
 
 
 
Figure 3.15 A sequence similarity network for MftD.  A sequence similarity network for the FMN-
dependent alpha-hydroxyacid oxidase family (IPR012133) shows the high sequence identity 
between members of this family (red) resulting clustering together of mycofactocin system flavin 
oxidoreductase (purple) together with other notable members such as lactate and mandelate 
dehydrogenase (green). 
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3.11 MftD Is an FMN Binding Protein.  
           To determine the role of MftD in the biosynthesis of mycofactocin, the mftD 
gene (mul_0774) was cloned from M. ulcerans Agy99, and the MuMftD protein 
was heterologously expressed in and anaerobically purified from E. coli. The 
protein was purified to homogeneity and >95% purity as indicated by SDS-PAGE 
(Figure 3.16A lane 1). Characterization of the as-purified MuMftD protein by 
UV−visible absorbance spectroscopy indicated the presence of a reduced flavin, 
which is characterized by the broad shoulder between 300 and 410 nm (Figure 
3.16C red). Upon exposure of the anaerobically purified protein to air, we observed 
a color change from colorless to intense yellow (Figure 3.16B). The absorbance 
spectrum of the protein shifted from a reduced flavin to that of an oxidized flavin, 
characterized by the dual absorbance maxima at 360 and 445 nm (Figure 3.16C, 
green). To determine which species of flavin was bound, MuMftD was heat 
precipitated and the soluble fraction was analyzed by HPLC. The retention time of 
the flavin in the soluble fraction was compared to authentic flavin standards of 
flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and riboflavin 
(Figure 3.16D). From the HPLC analysis, it was evident that the absorbance 
features of the cofactor bound to MuMftD originated from FMN, consistent with 
other members of the protein-fold family (200). Notably, when MuMftD was purified 
aerobically, the protein appeared to lose FMN during the isolation process. 
Consistent with this observation, analysis of MuMftD by analytical HPLC-SEC 
demonstrated that, upon oxidation, the protein releases the bound FMN (Figure 
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3.16E), in the absence of substrate. In our hands, we observed that the loss of 
FMN is irreversible. 
 
Figure 3.16 Characterization of MftD protein.  (A) MftD was purified to homogeneity as 
determined by SDS-PAGE analysis. Lane 1 contains the Goldbio BLUEstain Protein Ladder 
standard, lane 2 contains His6-purified MuMftD, and lane 3 contains His6-purified MsMftD. (B) 
Color change observed when the protein is exposed to oxygen indicating the oxidation of bound 
FMN upon oxygen exposure. (C) UV−vis spectral analysis of anaerobically prepared MftD indicates 
the presence of a reduced flavin (red). Upon exposure to air of the protein sample, the UV−vis 
spectrum shifts considerably, indicating that the flavin is oxidized. (D) High-pressure liquid 
chromatography analysis of the flavin-containing fraction of the protein precipitate (red) indicates 
that MftD likely binds FMN when compared to retention times of flavin standards (E) Analytical size 
exclusion chromatography of reduced and oxidized MftD shows that the purified protein migrates 
as a tetramer with a molecular weight of ~ 170 kDa. MftD loses > 50% of the bound FMN upon 
oxidation. Chromatograms were reported at 280 nm (black) for protein and 450 nm (red) for FMN. 
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3.12 Reconstitution of MftD Activity 
           To determine if the product from the MftE reaction is the substrate for MftD, 
reactions containing AHDP and MftD were carried out aerobically, and analyzed 
by HPLC. The aerobic addition of AHDP to MftD and subsequent analysis by HPLC 
does in fact give rise to a new species at a retention time of ∼15.8 min (Figure 
3.17A, green) with the concomitant disappearance of AHDP at ∼14.1 min. The 
associated kobs for the single turnover reaction was measured to be 0.010 ± 0.002 
min−1 (Figure 3.17B). Interestingly, the UV−visible absorbance spectrum for the 
new species is substantially different than that of AHDP, indicating that the 
resulting modification also impacted the electronics of the molecule (Figure 3.17 C 
and D). To ensure that this activity was not unique to MuMftD, the gene 
msmeg_1424, encoding for MsMftD, was cloned from M. smegmatis mc2155 and 
the protein was purified from E. coli (Figure 3.16A). The purified protein was used 
to set reactions with AHDP and analyzed by HPLC. As expected, the HPLC 
chromatogram for the MsMftD reaction showed similar results to that of MuMftD 
(Figure 3.17A, blue), indicating that AHDP is most likely the substrate for both Ms 
and MuMftD. Subsequent analyses were carried out solely with MuMftD and will 
refer to the protein as simply MftD.  
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Figure 3.17 HPLC analysis of MftD reactions.  (A) HPLC chromatograms of reactions containing 
AHDP (red), AHDP and MsMftD (blue), AHDP and MuMftD (green) indicate that AHDP is an active 
substrate for MftD. (B) Single turnover kinetic analysis of the MftD reaction monitored by HPLC. 
Triplicate reactions were carried out with 100 μM AHDP and 200 μM MftD. Data were fitted to a 
single exponential equation (green line) to determine the kobs. UV-vis spectra of (C) the substrate 
AHDP, and (D) the product MftD reaction named PMFT. 
 
3.13 HRMS analysis of MftD reactions 
           To determine the type of chemical modification imparted on AHDP by MftD, 
we analyzed the product of the reaction by high resolution mass spectrometry 
(HRMS). Consistent with the previous analysis of AHDP described above, the 
HRMS analysis of the AHDP [M + H]+ ion, reanalyzed here, was found to have a 
mass-to-charge ratio (m/z) of 235.1445 (Figure 3.18A, black), within 4 ppm of the 
predicted mass (C13H18N2O2, theoretical m/z = 235.1441 Da). HRMS analysis of 
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the ∼15.8 min MftD product provided a m/z = 234.1107 (Figure 3.18A, green). This 
mass is consistent with the loss of NH3 and the addition of a single oxygen atom 
to ADHP (C13H15NO3, theoretical [M + H]+ m/z = 234.1125). These results are 
inconsistent with our previous proposal suggesting that MftD could catalyze the 
formation of a catechol on the phenyl ring of AHDP. Instead, our HRMS analysis 
suggests that MftD might catalyze the oxidative deamination of AHDP, installing 
an α-keto moiety, resulting in the formation of 5-[(p-hydroxyphenyl)methyl]-4,4-
dimethyl- 2,3-pyrrolidinedione (Figure 3.18B, green) or herein referred to as 
premycofactocin (PMFT). Precedence for flavin-dependent oxidative deamination 
comes from D-amino acid oxidase (DAAO). DAAO’s function is to catalyze the 
flavin adenine dinucleotide (FAD)-dependent and stereospecific oxidation of D-
amino acid to form α-keto acids (192, 201). However, it should be noted that DAAO 
and MftD belong to different protein-fold families (202, 203).  
 
 
 
Figure 3.18 HRMS analysis of MftD modification reactions. (A) Analysis of the AHDP (black) 
and the MftD product (green) shows an ion with an m/z that is consistent with the loss of −NH3 and 
the addition of O. (B) From the HPLC and HRMS analysis, MftD is proposed to catalyze the 
oxidative deamination of AHDP (black) to form premycofactocin (PMFT, green). The theoretical 
m/z for the molecules are indicated above their structure.  
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3.14 NMR structural elucidation of the MftD reaction Product. 
          To confirm that MftD indeed catalyzes the oxidative deamination of AHDP 
and the subsequent formation of PMFT, 1D and 2D NMR studies were carried out 
on the isolated product. Reactions containing AHDP and MftD were performed on 
a large scale (∼2 mg of AHDP), and the HPLC purified MFT was analyzed by NMR. 
For 13C NMR, we used synthesized MftA to contain uniformly 13C labeled valine 
and uniformly 13C labeled tyrosine at positions Val29 and Tyr30. The heavy peptide 
was used in reactions with MftB, MftC, MftE, and MftD to generate the uniformly 
13C-labeled PMFT. This was required to increase the 13C NMR signal due to the 
limited quantities of isolated PMFT. Although we had already reported on the 1H, 
13C, and COSY NMR characterization of AHDP, we further analyzed it by HSQC 
2D NMR in this study. This allowed us to directly compare AHDP spectra to that of 
PMFT. Analysis of the COSY NMR spectra of the lactam region for both AHDP 
(Figure 3.19A, red) and PMFT (Figure 3.19A, green) showed some difference in 
the structure of the substrate and the product. Notably, the chemical shifts of the 
protons within the lactam region of PMFT are modestly shifted downfield by 0.1 - 
0.4 ppm. This downfield shift is accompanied by the disappearance of the Hα in 
the 1H NMR spectrum of PMFT (Figure 3.19A), suggesting that the Cα of the 
lactam was the site of modification. Consistent with this observation, 13C NMR 
indicated a drastic downfield shift of the Cα from ∼61 ppm in AHDP (Figure S 2B) 
to ∼210 ppm in PMFT (Error! Reference source not found.B). The chemical shift 
of the Cα is corroborated by HMBC spectra (Figure 3.19B), which showed long-
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range interaction between the protons on the geminal methyl and the Cα. Lastly, 
overlaid HSQC spectra of AHDP and PMFT showed the loss of the proton−carbon 
coupling associated with H−Cα (Figure 3.19C). Together, these NMR data provide 
strong evidence that MftD catalyzes the oxidative deamination of AHDP to form 
PMFT. 
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Figure 3.19  NMR analysis of MftD reaction product PMFT. (A) Overlaid COSY spectra of AHDP 
(red) and PMFT (green) showing the loss of the Hα signal. (B) HMBC spectrum of PMFT shows 
that the Cα has shifted downfield to ∼210 ppm. (C) Overlaid HSQC spectra of ADHP (red) and 
PMFT (green) show the loss of the H−Cα heteronuclear interaction. (D) Reference structure of 
PMFT with the important carbon annotated. (E) Summary of relevant NMR correlations on PMFT. 
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3.15 Role of oxygen in MftD reaction. 
           Having solved the structure of PMFT, we next set out to determine the 
source of the incorporated oxygen atom. Since MftD catalyzed a similar reaction 
to DAAO, we turned to its well-characterized mechanism for guidance. The DAAO 
reaction is described by the two-step oxidative deamination of the D-amino group 
on the amino acid (Figure 3.20A). To begin with, DAAO oxidizes the amino acid to 
an α-imino acid through a hydride transfer from the Cα to FAD (202). This is 
followed by a nucleophilic substitution by an activated water and the subsequent 
oxidation to form the ketone (201). We rationalized that MftD could carry out a 
similar reaction mechanism, which we describe in Figure 3.20B.  
 
Figure 3.20 Reaction mechanism of MftD. (A) Condensed Reaction Scheme for D-Amino Acid 
Oxidase (DAAO) and (B) for MftD 
 
 
          To determine if water was the source of the inserted oxygen, we carried out 
MftD reactions in 99% enriched 18OH2 and analyzed the resulting PMFT by HRMS. 
From this experiment, we expected to observe an enrichment of an PMFT ion that 
was consistent with a single 18O being incorporated (+2 m/z).  As expected, the 
mass spectrum of the reaction mixture carried out in 18OH2 showed two 
predominant ions (Figure 3.21A), one at the expected m/z for unlabeled PMFT ([M 
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+ H]+ m/z = 234.1125) and the other at a m/z = 236.1169, within 2 ppm of the 
expected mass for the 18O incorporated PMFT ([M + H]+ m/z = 236.1167). The 
percent incorporation was ∼65%, which is near the expected theoretical maximum 
of 87%. Conversely, when the reaction was carried out in 18O2, we did not observe 
any significant incorporation of 18O into the product (Figure 3.18B). The rate of 
back exchange was found to not significantly affect the overall incorporation of 18O 
into the product during the course of this experiment (Figure 3.21C). Therefore, 
these results are consistent with water being the source of the inserted oxygen 
atom in the MftD-catalyzed oxidative deamination of AHDP. 
         In the DAAO mechanism and the proposed mechanism for MftD, O2 is the 
final electron acceptor (201). To verify that molecular oxygen is required for MftD 
turnover, reactions were carried out anaerobically.  To achieve anoxic conditions, 
reactions were conducted in an anaerobic chamber and supplemented with 
glucose and glucose oxidase prior to the addition of MftD. Glucose oxidase 
catalyzes the oxidation of glucose to gluconate and hydrogen peroxide and is often 
added to reactions to achieve anaerobicity (204, 205). The subsequent HPLC 
chromatogram of the anaerobic reaction indicated only the presence of the starting 
material AHDP (Figure 3.21D). This suggests that molecular oxygen is required 
for the MftD activity. Since anaerobically purified MftD contains FMNH2, and since 
we did not observe any turnover of MftD, it is likely that O2 is required for the 
oxidation of FMNH2. Notably, MftD was inactive in reactions carried out under the 
same conditions but with the addition of NAD+ (Figure 3.21E), suggesting that the 
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nicotinamide could not fulfill the role of O2. Taken together, the results from this 
analysis is consistent with O2 being the final electron acceptor in MftD catalysis. 
 
 
Figure 3.21 Assessing the requirement of oxygen for MftD catalysis.  (A) High-resolution mass 
spectra of the MftD reaction carried out in 18OH2 showing the enrichment of the 18O-incorporated 
PMFT (red). The structures for natural abundance and enriched PMFT are shown above with their 
theoretical mass for the [M + H]+ ion. (B) Control experiments for HRMS spectra monitoring the 
incorporation of 18O into PMFT during MftD reaction in 16OH2/18O2. (C) HRMS control spectra for a 
60 min exchange experiment where 16O-PMFT was incubated in 18OH2 buffer. (D) HPLC analysis 
of MftD reactions under anaerobic (black) and aerobic (green) conditions suggests that molecular 
oxygen is required for catalytic turnover. The reference chromatogram for AHDP is shown in red. 
(E) Assessing MftD activity with NAD+. HPLC chromatogram of the anerobic reaction of MftD with 
AHDP (red) in the presence of NAD+ (black) shows no PMFT formation at 15.8 min. 
 129 
 
3.16 PMFT contains redox active center.  
           As stated previously, the structure of AHDP did not have an apparent 
physiologically relevant redox center. However, following oxidative deamination by 
MftD, we rationalized that the resulting α-keto-amide moiety could be the active 
site of PMFT. Indeed α-keto acids are a common 2e−/2H+ redox moiety and can 
be found in biologically important molecules such as pyruvate, α-ketoglutarate, and 
oxaloacetate. To provide insight about the possible redox behavior of PMFT, cyclic 
voltammetry (CV) was used to directly measure the midpoint potential of PMFT. 
Three-electrode CV experiments were carried out using a glassy carbon working 
electrode, an Ag/AgCl reference electrode, and a platinum counter electrode. 
PMFT was noncovalently adsorbed onto the working electrode using single-walled 
carbon nanotubes (SWCNTs) as a coabsorbent. CV measurements yielded a 
single signal that was observed between −100 and −400 mV as compared to the 
buffer/SWCNT control (Figure 3.22). From this measurement, the reductive and 
oxidative potentials were found to be −370 and −140 mV, respectively, and the 
overall midpoint potential to be −255 mV. We did not observe significantly 
differentiated peaks for two single electron transfer events; thus, we define the 
midpoint potential for the 2e−/2H+ transfer as −255 mV. 
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Figure 3.22 Cyclic voltammetry of PMFT. Overlaid cyclic voltammogram of PMFT/SWCNT (red) 
and buffer/SWCNT (black). Voltammetry of PMFT was measured at pH 7.0 and at 22 °C with a 
scan rate of 50 mV/s. 
 
 
 
 
3.17 PMFT is redox and functionally active in vitro. 
           Having shown that PMFT is redox active, we next postulated that it could 
be used to oxidize NADH in mycofactocin dependent dehydrogenases. M. 
smegmatis mc2155 carveol dehydrogenase (MsCDH, Msmeg_1410) was chosen 
as the model mycofactocin-dependent dehydrogenase to test this hypothesis since 
the R. erythropolis DCL14 homologue has been shown to catalyze the oxidation 
of carveol to carvone using 2,6-dichlorophenolindophenol (DCPIP) as an electron 
acceptor (206) and since it was known to copurify with NADH (182). This latter 
property is significant because it could allow us to monitor the PMFT-dependent 
oxidation of NADH to NAD+ by monitoring UV−visible absorbance at 340 nm 
(ΔεNADH 340 nm = 6.22 mM−1 cm−1). To demonstrate that PMFT could be used 
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as an oxidant, scanning UV−visible spectroscopic measurements were carried out 
with purified MsCDH (see Figure 3.23A for an SDS-PAGE). As shown in Figure 
3.23D, the incremental addition of PMFT resulted in a stoichiometric decrease in 
absorbance at 340 nm, suggesting that PMFT is mediating the oxidation of NADH 
to NAD+ on MsCDH. It should be noted that we did not observe the same oxidative 
activity toward free NADH (Figure 3.23C). Consequently, this implies that PMFT is 
biologically active with MsCDH and potentially with other mycofactocin-dependent 
dehydrogenases.  
           After finding that PMFT was capable of oxidizing NADH bound to a 
mycofactocin-dependent dehydrogenase, we next sought to couple PMFT to the 
MsCDH-catalyzed oxidation of carveol. To do so, MsCDH was incubated with 
excess amounts of carveol and PMFT in a stoichiometric ratio. The subsequent 
reaction mixture was analyzed by HPLC (Figure 3.23E). We observed a change in 
the retention time of PMFT in the chromatogram, from ∼15.8 to ∼14.9 min, with an 
accompanying change in the UV−visible spectrum (Figure 3.24 A and B). In 
addition, we observed a concomitant appearance of new species at a retention 
time of ∼19.5 min corresponding to carvone (Figure 3.23F). We expected that the 
species at ∼14.9 min is the reduced form of PMFT (PMFTH2). To confirm this 
hypothesis, we analyzed the HPLC-purified species by HRMS. As expected, 
HRMS analysis (Figure 3.24C) of the ∼14.9 min species provided an m/z = 
236.1267, which is consistent with the m/z of PMFTH2 (C13H17NO3, theoretical [M 
+ H]+ m/z = 236.1281). Taken together, the observation that PMFT oxidizes the 
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NADH on MsCDH, that PMFT facilitates MsCDH carveol oxidation activity, and a 
mass consistent with PMFTH2 provides compelling evidence that PMFT is a redox 
cofactor. 
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Figure 3.23 Analysis of MsCDH activity with carveol in the presence of PMFT. (A) An SDS-
PAGE of MsCDH shows the protein was purified to > 95% purity with a migration molecular weight 
of ~36 kDa (Lane 1 contains GoldBio BLUEstain Protein Ladder and Lane 2 contains MsCDH 
protein). (B) UV-Vis spectrum of MsCDH shows an absorbance at 340 nm suggesting that the 
protein contains NADH. (C) Overlaid UV−visible spectra showing the oxidation of MsCDH-bound 
NADH by PMFT. (D) Control scanning spectroscopic experiment showing that PMFT does not 
oxidize free NADH in solution. (E) HPLC analysis demonstrates that MsCDH is active towards 
carveol in the presence of PMFT (green). The chromatogram for PMFT is shown in green. (F) 
HPLC chromatograms of MsCDH reactions with carveol(brown) in the presence (blue) and absence 
(green) of PMFT. Carvone chromatogram was reported at 260 nm while PMFT and PMFTH2 
chromatograms were reported at 280 nm. 
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Figure 3.24 Analysis of the reaction product of MsCDH with PMFT.  UV-visible spectra of (A) 
PMFT before MsCDH reaction with carveol and (B) PMFTH2 after carveol transformation reaction. 
(C) HRMS analysis of the ∼14.9 min peak shows an ion with an m/z that is consistent with the mass 
of PMFTH2 (theoretical [M + H]+ m/z = 236.1281). (D) The proposed structure of PMFT following a 
2e−/2H+ reduction. 
 
 
 
 
3.18 PMFT is a physiological redox cofactor 
           To determine the efficacy of PMFT as a redox mediator, the apparent rate 
constant (kobs) governing the oxidation of MsCDH-bound NADH by PMFT was 
determined. To do so, time-dependent stopped-flow UV−vis spectrometry 
experiments were carried out at two PMFT concentrations, in triplicate each, 
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monitoring the oxidation of MsCDH-bound NADH at 340 nm (Figure 3.25A). Data 
were fitted to a single exponential decay, which yielded a kobs = 0.8 ± 0.1 s−1. To 
directly compare this rate to the rate of oxidation of MsCDH by DCPIP, we carried 
out similar stopped-flow reactions monitoring the absorbance of DCPIP at 600 nm 
(ΔεDCPIP 600 nm = 20.7 mM−1 cm−1, Figure 3.25B) due to spectral overlap with NADH. 
These reactions were fitted to a linear equation, which provided a kobs < 0.01 s−1, 
substantially slower than that observed for PMFT. Control stopped-flow 
experiments were carried out to ensure that DCPIP was not oxidizing MsCDH on 
the millisecond time scale (Figure 3.25C). While there is a slim possibility that 
DCPIP could oxidize MsCDH faster than the deadtime of the instrument (3 ms), 
the more likely scenario is that DCPIP is nonspecifically interacting with MsCDH, 
which leads to the slow rate of oxidation. Overall, the >100-fold rate enhancement 
of PMFT over DCPIP further indicates that PMFT is a physiological mediator for 
MsCDH. 
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Figure 3.25 Stop flow kinetic analysis of the oxidation of MsCDH bound NADH. (A) Analysis 
of a single turnover oxidation reaction with 160 μM MsCDH and 25 μM (red dashes) or 50 μM 
(magenta dashes) PMFT. (B) Analysis of single turnover oxidation reaction with 160 μM MsCDH 
and 60 μM (cyan) or 22 μM DCPIP (grey). Controls with DCPIP and buffer are shown in blue and 
black. The reduction of DCPIP was monitored at 600 nm during the reaction, sampling every 100 
ms. Each kinetic trace is an average of 3 individual experiments. The averages were fitted to a 
single exponential decay (magenta and red) to determine the rate constant. (C) Stopped-flow 
kinetic analysis of a single turnover oxidation reaction with 160 μM MsCDH (red) and 60 μM DCPIP 
and buffer (black) and 60 μM DCPIP. Data acquisition occurred every 1 ms. The inset of the same 
reaction shows that steep decrease in absorbance due to rapid oxidation of MsCDH was not 
present. 
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CHAPTER FOUR: DISCUSSION 
           Mycofactocin is a ribosomally synthesized and post translationally modified 
peptide natural product whose biosynthesis, structure and function, prior to this 
work, was unknown. Six genes were identified to be responsible for the 
biosynthesis of mycofactocin and the putative product was postulated to be the 
second member of the RiPP-derived redox cofactor(169). This assumption was 
solely based on bioinformatic studies that concluded that mycofactocin associated 
dehydrogenases might require mycofactocin for catalytic turnover and that the 
pathway appeared reminiscent to that of PQQ (169). To validate this hypothesis, 
research efforts were aimed at in vitro reconstitution of each enzyme in the 
pathway to gain insights into their role and functions during mycofactocin 
biosynthesis. Within a short period of time, two independent studies, one by our 
lab demonstrated that MftC catalyzed the oxidative decarboxylation of the C-
terminal tyrosine of MftA as the first step in the biosynthesis of mycofactocin (74, 
98). A subsequent study of the gene products of the pathway concluded that MftE 
hydrolyzed the last two residues of the decarboxylated MftA (185). However, a 
further mechanistic study by our lab demonstrated that MftC catalyzed an 
additional redox neutral cyclization step by converting the decarboxylated product 
to a lactam moiety (99).  
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           MftC is a member of the RS-SPASM protein family. Proteins within this 
family are known to bind two auxiliary [Fe-4S] clusters. However, there is no clear 
understanding of the roles of these clusters in radical SAM chemistry. While recent 
deposition of crystal structures of some RS-SPASM enzymes (e.g., anSME, PqqE, 
CteB, and SuiB) into the protein data base has provided some insights into the 
possible function of these auxiliary clusters, the rules by which to assign their 
function have not been established. For instance, in the biosynthesis of 
thermocellum, the RS-SPASM enzyme CteB was shown to install a thioether bond 
on the precursor peptide CteA. Both auxiliary clusters of CteB are in [4Fe-4S] state 
however, the Aux I cluster was found to be ligated by three cysteines with an open 
coordination site for substrate binding and orientation during catalysis (83). 
Another example is the RS-SPASM enzyme PqqE which is involved in the 
biosynthesis of PQQ. PqqE was shown to install a carbon-carbon crosslink on the 
precursor peptide PqqA. Whereas both auxiliary clusters of PqqE are ligated by 
eight conserved cysteine residues, the Aux I and Aux II clusters were shown to be 
in different configurations of [2Fe-2S] and [4Fe-4S] respectively and their exact 
role in catalysis has yet to determined. A third scenario can be found in anSME, a 
RS-SPASM protein involved in the maturation of Cys-type or Ser-type sulfatase. 
Unlike CteB and PqqE, both auxiliary clusters in anSME are fully ligated and in the 
[4Fe-4S] configuration. However, the precise catalytic role of these clusters in 
anSME is yet to be fully understood (117). 
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             In this dissertation, we have provided additional information regarding the 
roles of the Aux I and Aux II clusters in the RS-SPASM family. Similar to QhpD, 
PqqE, SCIFF, and AlbA (74, 76, 119, 191), the Aux I and Aux II clusters in MftC 
are required for modification of MftA but not for SAM cleavage. This may suggest 
that the Aux I and II clusters participate directly in the decarboxylation and 
crosslinking reactions on MftA by either binding the peptide, transferring 
electron(s) during catalysis, or a combination of both. Our bioinformatic and 
mutational analysis indicated that the Aux I cluster may be coordinated by at least 
three Cys residues (251, 269, and 323), potentially leaving an open coordination 
site. An open coordination site on the Aux I cluster would be indicative of a 
substrate binding role similar to that observed in CteB (83). However, since 
Cys258 is conserved, despite the little catalytic impact observed for the mutant and 
since guiding structural information for MftC is lacking, this proposal is limited.  
           The ability of MftC to catalyze two distinct chemistries: an oxidative and 
redox neutral reaction, in the same active site is very interesting. This chemistry is 
unique to the RS-SPASM family and suggests that MftC has the means to 
modulate the electrochemical environment within its active site for each catalytic 
step. The resting state reduction potential for the Aux I cluster is similar to what 
was measured for the same cluster in SCIFF maturase (193). This similarity 
suggests that the midpoint potential of the Aux I cluster in MftC may be modulated 
through substrate interaction or active site rearrangement to accommodate both 
oxidative and redox neutral chemistries. Unlike SCIFF, MftC catalyzes two distinct 
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chemistries on two electrostatically different compounds. In the first step, MftC 
catalyzes the oxidative decarboxylation of the MftA peptide, resulting in the α/β 
unsaturated bond on MftA** (Figure 1.21). Since the C-terminus of MftA is 
presumably deprotonated, the loss of the carboxylate would also result in the loss 
of a negative charge in the active site, which could influence the reduction potential 
of the Aux I cluster. Further electrochemical investigations of MftC in the presence 
of each substrate will be required to confirm this hypothesis. Although the potential 
role of the Aux I cluster in MftC catalysis has been provided, the role of the Aux II 
is yet to be determined. Despite behaving as two redox active centers, the redox 
potentials of the Aux I and Aux II clusters are very similar: within ~ -50 mV apart. 
This suggests that there is not a steep barrier for the reversible electron transfer 
between the two clusters. Indeed, the calculated difference in Gibbs free energy 
between the two clusters was found to be ~4.8 kJ/mol, which could allow for the 
reversible electron transfer between these clusters during MftC catalysis. These 
results together with the evidence that the Aux II cluster is required for catalysis 
suggests that the Aux II cluster may participate in electron shuttling in and out of 
the active site. 
           A common feature in RiPP biosynthesis is the processing of the 
functionalized peptide by peptidases after modifications have been imparted. This 
step generally occurs as a mechanism to cleave the leader peptide and liberate 
the biologically functional RiPP product. An example of this mechanism can be 
found in subtilosin biosynthesis where AlbE or AlbF hydrolyze the leader peptide 
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off the precursor peptide, SboA after it has undergone chemical transformations 
by AlbA (76, 207). An alternate scenario can be found in the biosynthesis of PQQ 
(Figure 1.16), where the two component protease, PqqF/G work in tandem to 
hydrolyze off the leader peptide on PqqA after chemical transformations by PqqE 
(154, 157, 159). This mechanism liberates the biologically relevant small molecule 
for further processing. When looking at the mycofactocin biosynthetic pathway 
through the lens of subtilosin or PQQ biosynthesis, one would expect MftE to 
hydrolyze the biologically relevant moiety from the precursor peptide. Indeed, 
previous work demonstrated that MftE hydrolyzes the last two residues from MftA* 
(185). This finding was solely based UHPLC, LCMS and derivatization assays and 
it was until later that our lab demonstrated that two products are formed from MftC 
catalysis (99). The two reaction products of MftC, MftA** and MftA* are isomers 
and so are the hydrolyzed products of MftE reaction.   
           In this dissertation, we clarified this conundrum by providing additional 
information regarding the hydrolysis of MftE. Similar to PqqF/G and AlbE/F, our 
experimental findings demonstrate that MftE is a metalloprotease that selectively 
hydrolyzes MftA* to form MftA (1-28) and the biologically relevant small molecule 
AHDP. However, unlike other metalloproteases that are capable of multiple 
turnovers, MftE catalyzes a single turnover reaction in our hands, suggesting that 
we a missing an important cofactor in our reaction. It should also be noted that 
MftE belongs to a protein fold family that is different from that of PqqF/G and 
AlbE/F. Whereas PqqF/G and AlbE/F are both Zn2+ metalloproteases belonging to 
 142 
 
the MEROPs peptidase M16 family, MftE on the other hand belongs to the 
peptidase amidohydrolase family of proteins which possess a binuclear metal 
binding center in their active site (159, 185). MftE was found to bind one mol 
equivalent of Fe2+ and mol equivalent of Zn2+ however, Fe2+ was observed to have 
the most catalytic impact on MftE hydrolysis, suggesting that zinc may be playing 
an auxiliary role. Nevertheless, guiding structural information for MftE and 
additional kinetic assays are required to adequately determine the role of both Fe2+ 
and Zn2+ in MftE hydrolysis reaction. 
           A bioinformatic study in 2011 suggested that mycofactocin could function 
as a redox cofactor, just like its brethren PQQ (169). A subsequent saturation 
transfer difference (STD) NMR study also concluded that mycofactocin is a 
putative redox cofactor utilized by mycofactocin-associated short chain 
dehydrogenases for multiple catalytic turnovers (182). This proposal is further 
corroborated by a recent in vivo expression studies that demonstrated that 
mycofactocin genes are required for assimilation of primary alcohols in the model 
organism M. smegmatis mc2155 (179, 180). While these findings have combined 
to suggest that mycofactocin is a redox cofactor, no direct evidence has been 
provided to date. In this dissertation, we have demonstrated that AHDP is an active 
substrate for MftD. We combined in vitro activity assays with HRMS and NMR 
structural workup to provide conclusive evidence that MftD catalyzes the oxidative 
deamination of AHDP to form the α-keto moiety called premycofactocin (PMFT). 
The formation of an α-keto moiety on PMFT led us to hypothesize that 
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mycofactocin could be redox active. To probe for redox activity, we used cyclic 
voltammetry to measure the midpoint potential of PMFT. Indeed, the cyclic 
voltammetry measurement showed a single signal with a midpoint potential of 
~255 mV. This midpoint potential is comparable to that of PQQ (-240 mV), a 
peptide-derived redox cofactor utilized by methanol and glucose dehydrogenases 
for multiple catalytic turnover (142, 145). This finding led us to further investigate 
whether mycofactocin-associated short chain dehydrogenases could directly 
recruit mycofactocin for catalytic turnover as postulated by Daniel Haft (169, 182). 
By combining activity assays with spectroscopic experiments, we provided direct 
evidence that PMFT oxidizes the NADH bound to MsCDH, a mycofactocin-
associated short chain dehydrogenase. MsCDH was found to cycle PMFT for 
multiple catalytic turnovers by transferring a 2H+/2e− onto PMFT to form PMFTH2, 
demonstrating that PMFT undergoes a 2e−/2H+ reduction by MsCDH.  
           These findings have coalesced to provide the first direct evidence that 
mycofactocin is a biologically active RiPP-derived redox cofactor utilized by 
mycofactocin-associated short chain dehydrogenases for multiple catalytic 
turnover. In addition, these findings continue to validate Haft’s hypothesis in 2011 
that mycofactocin is the second member of RiPP-derived redox cofactors.  
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CHAPTER FIVE: SUMMARY 
           In summary, the work presented in this dissertation has shed light on the 
structure, function and chemistries of each enzyme involved in the biosynthesis of 
mycofactocin. To begin with, we provided additional information regarding the roles 
of the auxiliary clusters in MftC, a unique RS-SPASM protein capable of catalyzing 
oxidative and redox neutral reactions in the same active site. In addition, we have 
clarified how mycofactocin is made by conclusively demonstrating that MftA*, the 
final product of MftC reaction is the precursor for mycofactocin biosynthesis. This 
specificity is dictated by the peptidase MftE. Lastly, we demonstrated for the first 
time that MftD catalyzes the oxidative deamination of AHDP, forming the redox-
active center in PMFT. We measured the midpoint potential of PMFT and provided 
the first direct evidence it is a biologically active redox cofactor utilized by 
mycofactocin-associated short chain dehydrogenases. Taken together, we provide 
the most direct evidence that mycofactocin is the second member of the RiPP-
derived redox cofactor family in addition to the sole quintessential member, PQQ.
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APPENDIX A: SUPPLEMENTAL DATA  
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Figure S 1 NMR spectra of the substrate and products of MftE reaction in 
D2O. Shown are (A) 1H NMR spectrum of MftA*, (B)1H NMR spectrum of MftA (1-
28), (C) 1H NMR spectrum of AHDP, (D)13C NMR spectrum of AHDP and (E) 
COSY NMR spectrum of AHDP. 
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Figure S 2. NMR spectra of MftD reaction substrate AHDP, in D2O.   NMR 
spectra of the substrate AHDP in D2O. Shown are 1H (A), 13C (B), COSY (C) and 
HSQC (D) NMR spectra. 
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Figure S3 NMR spectra of MftD reaction Product, PMFT in D2O. Shown are 1H 
(A), 13C (B), COSY (C) and HSQC (D) and HMBC (E) NMR spectra. 
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